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This thesis comprises three studies that examine the prevention and treatment of
oesophageal cancer.
Barrett's oesophagus is a pre-malignant condition. It is an attractive idea that
successful eradication ofBarrett's oesophagus could reduce the risk of development
of an oesophageal carcinoma. In the first study 12 patients with at least two
centimetres of specialised intestinal metaplasia were treated with Argon Plasma
Coagulation. Multiple biopsies were taken at baseline, and at two and six months
following treatment. These biopsies were analysed for histology, p53
immunostaining, and cell cycle abnormalities using flow cytometry. On follow-up
there was a trend for an increase in the number of squamous biopsies and a decrease
in the number of biopsies showing intestinal metaplasia. Three patients developed
persistent buried glands and a fourth patient developed an oesophageal carcinoma
during follow-up. There was no significant change in follow-up of either the p53
staining or the flow cytometry.
Only about a third of patients presenting with oesophageal cancer are suitable for
curative surgery. For the remainder, the aim of therapy is palliation of malignant
dysphagia and maintenance of a reasonable quality of life. The second study is a
randomised trial comparing the use of Nd:YAG laser therapy or insertion of an
expandable metallic stent in 52 patients for the palliation of malignant dysphagia.
Patients were assessed prior to treatment and thereafter at two monthly intervals for
assessment of dysphagia and quality of life using the SF36, HAD and EORTC-
QLQC30-OES-24 questionnaires. The laser patients survived significantly longer
than the stented patients, but this must be balanced against the increased cost of the
VII
laser therapy. Palliation of dysphagia was disappointing but did not differ between
the two groups. Quality of life was globally impaired in both groups at baseline.
Notably the stented patients had significantly more pain than the laser patients at the
two month follow-up.
The last study retrospectively examines the effect of radical radiotherapy on a cohort
of 60 patients with oesophageal cancer. This study revealed a one year survival of
40% and a five year survival of 0%. Half of patients experienced complications
during the treatment and a further 25% had post-radiation complications. Radical
radiotherapy can no longer be considered as appropriate therapy for oesophageal
cancer.
Oesophageal carcinoma is rapidly rising in incidence and is requiring increasing
expertise and resources. Further studies need to focus on optimising and evaluating
ablative techniques for Barrett's oesophagus and palliative treatments for
oesophageal cancer.
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PART ONE: INTRODUCTION & LITERATURE REVIEW
CHAPTER 1 -Barrett's oesophagus (A critical review of the literature)
1.1 Introduction
This thesis concerns aspects of oesophageal neoplasia. This includes a spectrum of
disease ranging from Barrett's oesophagus, recognised as the most important pre-
malignant condition, to therapy for established cancer.
The term 'Barrett's oesophagus' is still widely used, but the entity now recognised
in clinical practice differs substantially from Barrett's original description. Several
alternative terms have been suggested; these are based upon histological features,
but none is perfect, many are clumsy and none have achieved universal acceptance.
Problems of definition are addressed in more detail in the next section, but despite
its limitations, 'Barrett's oesophagus' is used in this thesis, since this term is
recognised by clinicians, pathologists and scientists.
1.2 History
Tileston first described the appearance of a columnar-lined oesophagus in 1906 '.
The eponym Barrett's oesophagus has been widely used since 1950, when Norman
Rupert Barrett, an eminent British surgeon, defined the oesophagus as " that part of
the foregut, distal to the cricopharyngeus sphincter, which is lined by squamous
epithelium" 2. He had also observed that in a number of patients the distal end of
what he presumed to be the oesophagus was lined with gastric-type columnar
epithelium. He suggested that in such patients, the squamous oesophagus was
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congenitally short, resulting in the tethering of a tubular part of the stomach within
the chest. Bosher and Taylor were the first to describe goblet cells in the columnar
lined oesophagus 3. The following year, Morson and Belcher described an
oesophageal adenocarcinoma adjacent to mucosa tending towards an intestinal type
and containing goblet cells 4.
A further report argued that the whole of the tubular intrathoracic structure described
by Barrett, anatomically and pathologically resembled the oesophagus rather than
the stomach because it had no peritoneal covering, had submucosal glands and
muscularis propria 5. A few years later in 1957, Barrett accepted this argument and
suggested that the condition should be called " lower esophagus lined by columnar
epithelium" 6 Nonetheless, the term Barrett's oesophagus has remained.
Although most authors writing during the 1950s observed an association with
oesophagitis, they still assumed that the columnar lined oesophagus was congenital.
Moersch was the first to imply that the columnar lined oesophagus was an acquired
condition due to gastro-oesophageal reflux disease (GORD)7
Throughout the 1960's and early 1970's there were several controversial reports
describing the histology of the columnar-lined oesophagus. Junctional epithelium,
fundic type epithelium and intestinal type epithelium with goblet cells were all
found lining the oesophagus 8;9. One study clarified the situation by describing the
histology of manometrically guided biopsies taken throughout the length of the
oesophagus in 11 patients 10. These patients were found to have either one or a
combination of three types of columnar epithelium lining the distal oesophagus;
these were classified as junctional, gastric fundic-like or a type with intestinal
2
metaplasia within specialised columnar epithelium. The latter was found adjacent to
the squamo-columnar epithelium.
The endoscopic diagnosis of Barrett's oesophagus was easy when long segments of
columnar epithelium extended well up the oesophagus and so most studies only
included such patients. Diagnostic difficulties arose when a biopsy was mistakenly
obtained from the columnar epithelium of the proximal stomach, giving a false
positive diagnosis of Barrett's oesophagus. This obviously could occur more easily
where there was a short segment of Barrett's oesophagus associated with
oesophagitis and a hiatus hernia.
In order to avoid this diagnostic dilemma, different investigators used different and
arbitrary diagnostic criteria for defining the extent of Barrett's oesophagus. This
varied from lengths of two cm to five cm of columnar lined oesophagus n"13. Thus,
the problem of false positive diagnoses was avoided, but short segments of
metaplastic epithelium in the distal oesophagus were not recognised.
Gradually, the association between Barrett's oesophagus and adenocarcinoma was
established. In the majority of patients with an adenocarcinoma associated with
Barrett's oesophagus, the adjacent mucosa was specialised columnar epithelium,
often showing dysplasia 14 Further studies confirmed that specialised columnar
epithelium predisposed to the dysplasia- adenocarcinoma sequence 15. Investigators
interested in the relationship between Barrett's oesophagus and adenocarcinoma
therefore opted to give Barrett's oesophagus the histological definition of specialised
intestinal epithelium 16;17. Again arbitrary values were chosen for the length of the
specialised epithelium required for the diagnosis.
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1.3 Definition and Diagnosis
Several problems exist in defining Barrett's oesophagus either by the extent of the
columnar lining or by the presence of intestinal metaplasia. These will be considered
in turn.
The ability to define Barrett's oesophagus by the extent of the columnar lining
depends on the accuracy of definition and identification of the gastro-oesophageal
junction. Unfortunately anatomists, radiologists, physiologists and endoscopists
have failed to reach a consensus on how to identify its precise location. Criteria used
by anatomists such as the peritoneal reflection are not clinically useful. Physiologists
use manometry to identify the lower border of the lower oesophageal sphincter and
use this as their definition of the gastro-oesophageal junction. However, the lower
oesophageal sphincter is difficult to define endoscopically and one study has shown
big differences in the manometric and endoscopic position of the lower oesophageal
sphincter 18. It has been suggested that the gastro-oesophageal junction lies at the
point where the tubular oesophagus flares and the proximal margin of the gastric
folds begin12. In reality the oesophagus is a dynamic organ and its appearance is
constantly changing by peristaltic waves. Few studies address these difficulties, and
furthermore, there is no gold standard against which to judge the criteria.
If the gastro-oesophageal junction cannot be correctly located, then any estimate of
the length of the columnar lining will be inherently imprecise. In addition, if
Barrett's oesophagus is defined by imposing some arbitrary length in the diagnostic
criteria, patients with shorter segments than this (perhaps with malignant potential)
will be ignored.
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Others have attempted to define Barrett's oesophagus merely by the presence of
specialised intestinal metaplasia, thus drawing away from Barrett's original
description. This definition is not without its problems. Intestinal metaplasia of the
gastric cardia does occur and if biopsies are accidentally taken from below the
gastro-oesophageal junction, an incorrect diagnosis may be made. It is not known
whether such intestinal metaplasia has a similar aetiology and prognosis as Barrett's
oesophagus, and currently they should be considered separate entities. In addition,
intestinal metaplasia may be patchy within a segment of columnar lined epithelium,
and sampling error may lead to falsely negative results.
More recently, there has been growing recognition of endoscopically inapparent
intestinal metaplasia at the gastro-oesophageal junction. Several studies have been
designed to examine this phenomenon. In the earliest study in 1994, consecutive
patients had biopsy specimens taken from the squamo-columnar junction
irrespective of its appearance and location19. Among 142 patients without
endoscopically apparent Barrett's oesophagus, 26 (18%) had specialised intestinal
metaplasia in the biopsy. Four further studies have confirmed that short,
inconspicuous segments of Barrett's oesophagus can be found frequently at the
20 23
squamo-columnar junction in unselected patients presenting for endoscopy ' .
Barrett's oesophagus has been associated with GORD and the development of
adenocarcinoma. Only one ofmany studies reported an association of short segment
Barrett's and GORD. Although very short segments of Barrett's oesophagus have
been associated with adenocarcinoma, the cancer risk for patients with short
segments of intestinal metaplasia in the distal oesophagus is not known 24"26. Thus, it
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may not been justified to include both patients with short and long segments of
columnar lined oesophagus under the same diagnostic category.
Spechler has proposed an alternative system of definitions that does not rely upon
imprecise endoscopic measurement27. Any length of columnar epithelium, observed
endoscopically should be referred to as the columnar lined oesophagus, and
histology further distinguishes columnar lined oesophagus with specialised intestinal
metaplasia from columnar lined oesophagus without specialised intestinal
metaplasia. As the risk of adenocarcinoma appears to be related to the length of the
oesophageal intestinal metaplasia, it is still important to measure its extent, even
though these measurements are imprecise 28. Spechler suggests that is clinically
more valid to use a descriptive definition, for example, columnar -lined oesophagus
with 10 cm of intestinal metaplasia, for each patient than simply using the more
ambiguous term of Barrett's oesophagus. Where biopsies taken from an apparently
normal gastro-oesophageal junction reveal specialised intestinal metaplasia the term
specialised intestinal metaplasia at the oesophagogastric junction should apply.
1.4 Epidemiology
Barrett's oesophagus is mainly a disease of the Western male and is rarely reported
in the Orient or third world countries. Approximately 12% of patients endoscoped
for symptoms of reflux disease will have Barrett's oesophagus. In a population-
based study, the clinical prevalence of Barrett's oesophagus was 22.6/100,000 but
this rose by 21 fold in an autopsy series 29. The prevalence of Barrett's oesophagus
in unselected dyspeptic patients presenting for endoscopy is approximately 1%30.
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1.5 Aetiology
It is widely assumed, although not proven, that Barrett's oesophagus develops when
the normal squamous oesophageal epithelium is replaced by columnar epithelium
during the process of healing after an acute injury to the oesophageal mucosa. Acute
oesophageal mucosal injury alone, however, is not sufficient to induce columnar cell
metaplasia because damaged squamous oesophageal epithelium is usually repaired
by squamous epithelial regeneration. A chronically abnormal environment in the
oesophagus due to GORD during the process of healing appears to be a prerequisite
for the development of Barrett's oesophagus. In most patients Barrett's oesophagus
seems to be the result of excessive reflux of gastric acid into the oesophagus which
causes the acute mucosal injury and also provides the abnormal environment during
the healing phase which predisposes to columnar metaplasia. It is thought that reflux
of acid causes inflammatory injury to the squamous epithelium. A multipotential
basal cell re-epithelialises the ulcerated area and through continued reflux these may
then differentiate into metaplastic epithelium.
This theory is supported by the observation of increased oesophageal acid exposure
in over 90% of patients with Barrett's oesophagus, the development and proximal
progression of Barrett's mucosa during long-term follow-up of patients with
gastroesophageal reflux and the induction of columnar oesophageal metaplasia in
experimental models of chronic gastroesophageal reflux31"36.
Compared with patients with GORD who do not have Barrett's oesophagus, both the
quality and quantity of the refluxate appear to be different than in patients with
Barrett's oesophagus. Ambulatory 24-hour oesophageal pH monitoring
demonstrated a markedly increased frequency and duration of reflux episodes
7
compared with patients with no columnar metaplasia 37;38. One study has shown that
cisapride may be effective by preventing this reflux 39.
Increased oesophageal acid exposure appears primarily to be due to a reduced lower
oesophageal sphincter pressure 37;40"42. When lower oesophageal sphincter pressures
are measured using radially orientated pressure transducers, a mechanically
defective sphincter can be documented in over 95% of patients with Barrett's
oesophagus 43. Ineffective oesophageal clearance function due to failure of
peristaltic activity within the body of the oesophagus further prolongs oesophageal
exposure to gastric content 44 One study has shown that the propulsion of a bolus in
the distal oesophagus and, consequently, clearance of refluxed gastric contents,
depends on peristaltic contractions with a minimum amplitude of 30-40mmHg45.
Both standard and 24- hour manometry of the oesophageal body show an increased
prevalence of ineffective oesophageal contractions in patients with Barrett's
oesophagus 33;41;46 Combined 24-hour manometry and pH monitoring demonstrate
that, ineffective contractions in the oesophageal body correlate with the prolonged
duration of individual reflux episodes 46;47.
Barrett's oesophagus can develop after total gastrectomy and this indicates that
reflux of acid is not essential for the development of Barrett's oesophagus 48;49.
Studies in rats have shown that after exposure to a carcinogen oesophageal
squamous cell carcinoma will develop. Following an oesophagoduodenostomy
(allowing the reflux of duodenal and gastric juices) 30% develop adenocarcinoma,
whereas if in addition a gastrectomy is carried out (permitting only duodenal reflux)
87% will develop adenocarcinoma 50. This suggests a synergism between gastric and
duodenal juices; gastric juice being protective and duodenal content carcinogenic.
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In contrast, the toxic effect of duodenal reflux on the human oesophagus is less clear
partly because of difficulty in measuring the refluxate. Recently, studies using
aspiration and chemical analysis of gastric contents have promoted further
discussion. Aspiration from the stomach or oesophagus and subsequent chemical
analysis of the aspirate permits direct measurement of bile and pancreatic enzyme
concentrations. Stein et al have shown that after a meal, total bile acid concentration
in the oesophagus was significantly increased in patients with GORD 51. There was
no difference in the quantity or activity of Trypsin between normal volunteers and
patients with GORD. In contrast the bile acid concentration in the refluxed gastric
juice was markedly increased in patients with a stricture or Barrett's oesophagus
compared to normal volunteers.
A fibreoptic system for circadian monitoring of biliary duodeno-gastric and
duodeno-gastric-esophageal reflux (Bilitec 2000 System) has been developed by
Becchi et al 52. Kauer et al used this system to evaluate the severity and circadian
pattern of bile reflux in a series of patients with GORD 53 Patients with Barrett's
oesophagus had a significantly higher prevalence of abnormal oesophageal bilirubin
exposure than those with oesophagitis or no injury. They also had a higher bilirubin
exposure than those without Barrett's oesophagus. The majority of oesophageal
bilirubin exposure occurred when the pH of the oesophagus was between 4 and 7.
Another group has also confirmed that patients with GORD complicated by Barrett's
oesophagus have a higher bile reflux than patients with uncomplicated GORD 54
Stein et al have further demonstrated that patients with early adenocarcinoma in
Barrett's oesophagus had a significantly higher prevalence of oesophageal bile
exposure than patients with Barrett's oesophagus but no adenocarcinoma 55.
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The rise in the frequency of oesophageal adenocarcinoma parallels the increased use
of H2 Receptor Antagonists (HRA) and Proton Pump Inhibitors (PPI's). It is
postulated therefore that chronic acid suppression may therefore be detrimental by
allowing reflux of duodenal contents through the alkalinised stomach environment.
Whether duodeno-gastro-oesophageal reflux is responsible for the dramatic increase
of adenocarcinomas of the gastro-oesophageal junction needs further investigation.
If this is the case, future research might include the use of bile binding agents,
prokinetic agents and Helicobacter pylori eradication in preventing Barrett's
oesophagus and adenocarcinoma. The effect of PPI's on the content of the
oesophageal refluxate also needs to be explored.
In addition to environmental factors, a genetic predisposition also appears to
contribute to the development of Barrett's oesophagus. Familial occurrence of
columnar cell lining of the distal oesophagus has been described in monozygotic and
non-identical twins 33;56;57. However it remains unclear whether genetic
abnormalities directly predispose to columnar metaplasia or result in increased
58
gastroesophageal reflux with subsequent development ofBarrett's oesophagus
1.6 Risk of oesophageal cancer
Patients with Barrett's oesophagus have an increased risk for the development of
oesophageal adenocarcinoma. The relative risk of developing cancer within Barrett's
oesophagus is difficult to measure. Prevalence rates of Barrett's associated
adenocarcinoma tend to overestimate its true prevalence, as benign disease tends to
be asymptomatic.
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A number of reports have evaluated the incidence of oesophageal cancer in patients
with Barrett's oesophagus. These are summarised in Table 1.1. A distinction should
be made between prospective and retrospective follow-up studies. Several of the
earlier studies were retrospective, patients with previously diagnosed Barrett's
oesophagus were traced years later to find how many had developed clinically
diagnosed cancer 59"61. Prospective studies, in which patients had regular endoscopic
follow-up with biopsies, are more likely to include early cancers 62;63. Short-term
follow-up studies may have overestimated the longer-term cancer risk, due to the
presence of microscopic adenocarcinomas not detected at initial endoscopy.
Retrospective follow-up studies may have underestimated the risk because goblet
cell metaplasia was not an entry requirement59;61. Patients might have been included
who did not have true Barrett's oesophagus.
Several studies have shown that the length of the columnar -lined oesophagus is
significantly related to the risk of carcinoma 64;65. One study showed that a doubling
of the length resulted in a 1.7 times increased risk 65. Iftikar et al also showed that
smokers had a 2.3-fold increased risk as compared to non-smokers. Another group
found that no patient with a columnar lined oesophagus of less than 8cm developed
dysplasia or adenocarcinoma64
Identification of dysplasia within Barrett's mucosa identifies patients at increased
risk of developing an adenocarcinoma. The presence of dysplasia predates the
development of adenocarcinoma. Neoplastic progression in Barrett's oesophagus
develops within the metaplastic columnar epithelium when genetic changes occur
that lead to the development of dysplasia. Dysplasia is neoplastic epithelium that
remains confined within the basement membrane of the epithelial surface. The
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accumulation of additional genetic changes within the dysplastic epithelium may
lead to the development of adenocarcinoma.
At initial endoscopy, dysplasia is found in 11-37% of all cases of Barrett's
oesophagus. 10;66;67 in follow-up, a further 12-18% of the patients will develop
dysplasia over a period of 3 to 5 years 66;67. In one series, as many as 67% of
patients with low-grade dysplasia developed high-grade dysplasia or
adenocarcinoma 68. When low grade dysplasia develops, progression to high grade
• • 66 67
dysplasia is not inevitable, and regression of dysplasia has been reported ; .
Although high grade dysplasia can exist for several years before progressing, the
majority of patients will eventually develop adenocarcinoma 66;67. In a number of
retrospective studies, dysplasia was present in the histological specimens of 35-91%
of patients with oesophageal adenocarcinoma 13;69;70. Furthermore, high-grade
dysplasia is strongly associated with foci of adenocarcinoma 70-74 In a recently
published series, eight of 11 patients (73%) who underwent surgical resection
because of high-grade dysplasia had invasive adenocarcinoma in the resection
specimen 75. In a second series, 13 of 30 patients (43%) undergoing surgery for
severe dysplasia had an invasive adenocarcinoma found in the resected oesophagus
76
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1.7 Screening and surveillance
Barrett's oesophagus is the most important risk factor for the development of
oesophageal adenocarcinoma. As this has the most rapidly increasing incidence of
• • • 86 88
any cancer in the USA and UK, a surveillance programme is attractive " .
Oesophageal cancers have a long, asymptomatic growth phase and it is assumed that
surveillance will allow early detection and treatment of adenocarcinoma and will
improve the prognosis. Numerous factors impact on the efficacy of surveillance in
Barrett's oesophagus. These include the natural history of Barrett's and
adenocarcinoma, the costs and complications of endoscopy, the cost and mortality
and morbidity of oesophageal resection.
To estimate the potential benefit of surveillance, we need to know what the outcome
might have been without surveillance. The best way to do this would be a controlled,
randomised prospective study comparing surveillance versus no surveillance. This,
however, would be a massive undertaking and seems unlikely to happen. The
incidence of cancer in Barrett's oesophagus is a critical factor in predicting benefit
from surveillance. As indicated above the assessment of cancer risk is in itself full of
difficulties, and varies considerably between studies (Table 1.1). Additionally, a
sizeable percentage of patients with known Barrett's oesophagus are not suitable
candidates for oesophagectomy because of age or concurrent disease, and early
diagnosis is unlikely to significantly affect their outcome, unless strategies for local,
non-surgical treatment can be developed. Patients undergoing surveillance may still
die of oesophageal cancer or complications of resectional surgery.
In one of the largest studies from the Netherlands, 155 patients seen between 1973
and 1986, but not entered into a surveillance programme, were traced in 1994 89.
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Seventy-nine had died, but death was only related to oesophageal cancer in two
cases (2.5%), one from metastases and one from postoperative complication. Six
further cases had oesophageal cancer, three of who were still alive following
oesophageal resection, and the other three had died of unrelated causes. These
authors concluded that their patients would not have benefited from an endoscopic
surveillance programme.
Wright et al reviewed data from a surveillance programme of 166 patients with
62 • •Barrett's oesophagus who underwent annual endoscopic surveillance . Six patients
had developed cancer. The screened group had a significantly earlier stage than a
control group of unscreened cancers. In a more recent study a clinicopathological
comparison was made between patients who initially presented with oesophageal
adenocarcinoma and those in whom the cancer had been detected during
surveillance of Barrett's oesophagus 90. They showed that surveyed patients had
significantly earlier stages and improved two year survival than non-surveyed
patients.
The cost of surveillance programmes has been estimated. In the study by Wright et
al, the cost of detecting one cancer was £14 868 for men and £42 084 for women 62.
Another American study using retrospective data estimated that the cost of detecting
one cancer through an annual surveillance scheme would be $62,000 11. Costs would
in both cases now be considerably higher.
Provenzale et al performed a decision analysis study to assess the efficacy of
surveillance in Barrett's oesophagus on the basis of a cancer risk of 1 cancer per 75
patients-years of follow-up 91. They concluded that when both quality and length of
life were considered, endoscopy every 2-3 years would be the most effective policy,
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although this would be very expensive. Endoscopy every 5 years would increase life
expectancy with a cost effectiveness similar to other common medical practices.
They also pointed out that if the cancer incidence were less that 1 in 200 patient
years, no surveillance would be the preferred strategy, because the risks of
surveillance and oesophagectomy outweighed any benefit in length and quality of
life. This study has received much criticism for making unsubstantiated
assumptions. For example, they assume a resection rate of 49% for unscreened
cancers and a 75% resection rate for screened cancers. They also assume only a 64%
five year survival for cancers detected by the screening programme.
Further problems in the diagnosis of dysplasia through a surveillance programme
relate to sampling error. Dysplastic mucosa may occupy most or the entire
oesophagus or it may be limited in extent. Thus, the endoscopist must thoroughly
sample the mucosa in order to avoid missing small areas of dysplasia or carcinoma.
Four-quadrant biopsies at intervals of 2cm or less throughout the length of the
Barrett's segment, combined with additional biopsies of any endoscopic lesions
produces excellent correlation between the pre-operative endoscopic diagnosis and
the final diagnosis in the resected specimen 92;93.
If surveillance is to be recommended, how frequently should this be undertaken?
Until recently most authorities would have advised annual endoscopic surveillance,
however this has now shifted and recommends screening frequencies between 2-5
years as long as there is no focal abnormality on endoscopy and no dysplasia on
biopsy 94;95. Of concern with such a policy is the possibility of interval cancers.
Indeed one study has shown that 50% of the cancers detected by an annual
surveillance programme were detected after less than two years 62.
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Currently, most oesophageal adenocarcinomas are found in individuals not known to
have Barrett's oesophagus. Most cases of Barrett's oesophagus are unrecognised,
and therefore surveillance of patients with known Barrett's oesophagus will have a
minimal impact on the overall death rate of oesophageal carcinoma. Only one case
of Barrett's oesophagus in 20 is detected in life 29. As about 10% of adults have
symptoms of GORD, a large population of patients is at risk for developing or
harbouring Barrett's oesophagus. The prevalence of Barrett's oesophagus in patients
with GORD is about 12%42. Two studies have confirmed that this figure is even
higher in patients with complicated reflux disease, such as oesophagitis or stricture
42;96. Previous work has suggested that the longer a patient has GORD symptoms the
greater likelihood of having Barrett's oesophagus 97;98. These findings have lent
support to the recommendation of many experts to limit screening for Barrett's
oesophagus to patients with reflux symptoms of 5-year duration or longer 99.
Reluctance for screening for Barrett's oesophagus is also related to the necessity for
endoscopy and biopsy to establish the diagnosis.
1.8 Histology
Barrett's oesophagus is confirmed when biopsies reveal columnar epithelium on
histological examination. Three histological types of Barrett's epithelium have been
described: a specialised 'intestinal' type with villous architecture and goblet cells
(Figure 1.1); a gastric fundic type with both chief and parietal cells; and a cardiac
type with simple mucous glands, but no other features 10. Specialised intestinal
epithelium is a pre-malignant, metaplastic change 13;69, whilst identification of
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cardiac or fundic columnar metaplasia has a considerably lower risk for malignant
transformation.
Dysplasia is defined as unequivocal neoplastic transformation which is
distinguishable from reactive and regenerative change. It is classified by guidelines
used for assessment of colonic dysplasia in inflammatory bowel disease, and
modified for application to the oesophagus 100;101. A diagnosis of dysplasia is based
on the severity of both architectural and cytological transformation indicating
neoplastic transformation. Architectural changes include budded, branched, crowded
or irregularly shaped glands. Low grade dysplasia is characterised by nuclear
pleomorphism, hyperchromatism and loss of nuclear polarity, but with limited
nuclear stratification. High-grade dysplasia is manifest as loss of nuclear polarity,
increased nuclear-cytoplasmic ratio, increased mitosis, nuclear hyperchromatism,
with crowding and stratification of nuclei extending from the basement membrane to
the luminal surface. The diagnosis of dysplasia and its varying degrees of severity
may differ between pathologists. In a study of eight experienced pathologists, there
was an 86% interobserver agreement over the diagnosis of high-grade dysplasia, but
a diagnosis of dysplasia or low-grade dysplasia was more variable with only 58 and
75% agreement respectively 102. Therefore it is recommended that two independent
pathologists should confirm the diagnosis of dysplasia.
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Figure 1.1 Pathology slide of Barrett's epithelium with specialised intestinal
metaplasia (x25 magnification)
20
For this reason, researchers have searched for a better indicator for risk ofmalignant
change in columnar- lined oesophagus, largely using flow cytometry to look for
changes in DNA ploidy and either immunohistochemistry or polymerase chain
reaction (PCR) to look for p53 gene abnormalities.
1.9 Molecular and cytological events in the development of Barrett's
oesophagus
1.9.1 p53
Lane and Crawford first discovered the p53 gene in 1979. The journal "Science"
named it in 1993 103. p53 has a role in the regulation of the normal cell cycle and in
104
tumongenesis
1.9.1.1 Action ofp53 in Normal Cells
The normal cell cycle consists of four phases Mitosis (M phase), a gap (Gl), DNA
synthesis (S phase), and another gap (G2). Gl is a variable period when the cell is
actively functioning; cells may enter the proliferating cell cycle or become dormant.
In the S phase, DNA replication occurs. G2 is the brief phase when the cell prepares
for the initiation of mitosis. The M phase represents mitosis in which identical
genetic material is apportioned to daughter cells.
p53 regulates the cell cycle and loss of this regulation through p53 malfunction
contributes to many cancers. p53 appears to act as a "guardian of the genome" by
behaving as a tumour suppresser gene and transcription factor. DNA damage
upregulates p53 which then stops the cell cycle at the Gl-S checkpoint and
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stimulates DNA repair. p53 slows the cell cycle by acting as a transcription factor
for Wild-type activated fragment 1(WAF1) whose product (p21) regulates cyclin
dependent kinases. Binding of p21 to cyclin-dependent kinases leads to a slowing of
the cell cycle at the Gl-S transition. p53 stimulates DNA repair through its
interaction with ERCC3 (Xeroderma pigmentosum group B or XPB) and a growth
arrest and DNA damage inducible gene (GADD45). However, ifDNA damages too
severe, p53 pushes the cell into programmed cell death (apoptosis).
1.9.1.2 Failure of p53
Failure of p53 results in loss of the Gl-S checkpoint and of the p53 promoted DNA
repair mechanisms. Loss of p53 function occurs when cells are in transition from the
precancerous state to overt cancer.
For p53 to fail, both of its alleles must be eliminated The most common way to lose
the effect of both alleles is to destroy the function of one by a mutation and to
remove the second allele entirely from the other chromosome. However, a p53
mutation in only one allele without loss of the other may still cause loss of normal
p53 function. p53 proteins join together in vitro. If one p53 member of the complex
is abnormal, the whole complex will not function correctly. As mutant p53 usually
has a longer half- life than the wild-type protein, transcription at the same rate
results in accumulation of the mutant p53. Thus, most of the p53 complexes will
then contain mutant p53 and be inactive. This is called the dominant negative effect.
This accumulation is the basis for the immunohistochemical detection of p53 protein
overexpression.
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1.9.1.3 Measurement of p53 and p53 mutations
p53 gene alterations can be studied by a variety of techniques including the
polymerase chain reaction (PCR) and sequence analysis or by single stranded
conformation polymorphism analysis (SSCP). Overexpression of p53 protein can
also be detected by immunohistochemical staining for specific anti-p53 antibodies.
Theoretically, p53 overexpression is an indirect method of detecting a p53 gene
mutation, although some studies have shown that not all p53 mutations cause p53
protein overexpression and that p53 overexpression may exist without a p53
mutation. One study examined p53 mutations and p53 overexpression in 10 patients
with Barrett's metaplasia alone and 10 with Barrett's metaplasia and carcinoma. In
the first group, one out of three patients who were p53 positive showed no p53 gene
mutation and three out of five patients who had a p53 mutation were negative for
p53 protein overexpression. In the second group, four out of six patients positive for
p53 showed no p53 gene mutation 105. Another study has also measured both p53
overexpression and p53 mutations in 17 patients with oesophageal adenocarcinoma
106 One patient was p53 positive but showed no detectable p53 gene mutation,
whilst five patients had a detectable mutation without evidence of p53
overexpression. These latter patients showed a chain-terminating mutation, resulting
in the synthesis of a truncated protein that was not detectable by
immunohistochemistry.
1.9.1.4 p53 immunoreactivity in Barrett's oesophagus
The appearance of p53 protein in Barrett's oesophagus and oesophageal carcinoma
has been well documented by several investigators. In Barrett's oesophagus
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complicated by adenocarcinoma, p53 overexpression has been found in 53% to 87%
of specimens.
In one study, a p53 mutation was found in 92% of patients with oesophageal
carcinomas, whereas, overexpression of p53 protein was only detected in 62% of
patients 107 In a later study, p53 mutation was found in only 55% of patients with
oesophageal carcinoma 108 Ramel et al measured p53 using flow cytometry in
patients with Barrett's oesophagus and adenocarcinoma in relation to the
histological grade 109. He found p53 to be positive in the 5% of patients who did not
have dysplasia, in 15% of patients with indefinite/low grade dysplasia, in 45% of
patients with high grade dysplasia and in 53% of patients with adenocarcinoma.
Another study has shown that in patients with a p53 positive adenocarcinoma, p53
overexpression only occurs in the adjacent mucosa in the presence of severe
dysplasia uo. Younes et al undertook immunohistochemical staining for p53 in
Barrett's epithelium in 54 patients ni. In 114 specimens they observed positive p53
in Barrett's epithelium in 0%, 9%, 55% and 87% of specimens interpreted as
negative for dysplasia, indefinite/low-grade dysplasia, high-grade dysplasia and
adenocarcinoma respectively. In a follow-up analysis of 24 patients, positive
staining was observed at the time of progression to high grade dysplasia in two out
of three patients, one of whom was originally p53 positive but with indefinite/low
grade dysplasia.
Campomnosi et al examined p53 and k-ras gene alterations in 30 patients with
Barrett's oesophagus 112. None of the cases showed K-ras mutations whereas 12
patients showed p53 mutation. This mutation was significantly associated with
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intestinal metaplasia. This finding may explain why intestinal metaplasia is most
closely associated with the development of adenocarcinoma.
Polkowski et al assessed the clinical value of p53 and Ki67 as a marker for tumour
progression in Barrett's oesophagus 113. Thirty-two specimens were examined with
varying degrees of dysplasia. P53 was not detectable in any specimen with no
dysplasia, in 1/5 indefinite dysplasia areas, in 6/11 low grade dysplasia areas and in
8/9 high grade dysplasia areas. The frequency of p53 accumulation increased
significantly with increasing grade of dysplasia.
1.9.1.5 p53 as a prognostic marker in Barrett's oesophagus
p53 may be useful as a prognostic marker in Barrett's oesophagus. As indicated in
the studies above, p53 protein accumulation in Barrett's oesophagus correlates with
dysplasia. One recent study has aimed to determine the sensitivity and specificity of
p53 accumulation as a marker of malignant potential in Barrett's metaplasia 114
They showed that five out of nine patients with low grade dysplasia and positive p53
developed high grade dysplasia or carcinoma. Whereas, none out of 16 patients with
low grade dysplasia and negative p53 developed high grade dysplasia or carcinoma.
The mean follow-up was 40 months. They conclude that p53 is more specific for the
development of high grade dysplasia or carcinoma than the presence of low grade
dysplasia. They suggest that the sub group of patients that have low grade dysplasia
and express p53 should be followed up by regular surveillance. However, not all
adenocarcinomas overexpress p53, suggesting that a subset of patients with Barrett's
oesophagus will undergo malignant transformation despite negative staining for p53
protein. This has been observed in at least one patient who showed neoplastic
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progression without detectable p53 accumulation m. Therefore further research into
additional prognostic indicators is required.
One recent study has measured anti-p53 antibodies in patients with Barrett's
oesophagus or oesophageal carcinoma. p53 antibodies were detected in 4 of 36
patients with Barrett's oesophagus, one of whom later progressed to
adenocarcinoma. Out of 33 patients with oesophageal cancer 10 had detectable p53
antibodies, two of whom had them detected prior to the diagnosis of cancer. The
authors conclude that those patients with Barrett's oesophagus and oesophageal
cancer can develop p53 antibodies that may predate the clinical diagnosis of
malignancy. Obviously, a larger population of patients with Barrett's oesophagus
needs to be studied to confirm these findings 115.
p53 may prove to be a useful adjunct to histology in assessing which patients with
Barrett's oesophagus are most at risk for developing a carcinoma. This may permit
more accurate selection of a sub-group of patients who would benefit from a
Barrett's surveillance programme. Further research needs to be done in this area.
A variety of novel techniques are being developed to ablate Barrett's oesophagus
including laser therapies and photodynamic therapies. The long term effect of these
treatments and whether they are able to halt neoplastic progression in Barrett's
oesophagus is unknown. In particular, changes in p53 expression following such
treatments have not been explored.
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1.9.2 Flow cytometry
Flow cytometry is based on the stoichiometric reaction of fluorescent dyes with
DNA. Cells in the GO/1 phase have a diploid amount of DNA. , cells undergoing
mitosis have a double diploid amount and those in S phase have an intermediate
amount. If cells contain an abnormal amount of DNA (aneuploid) they can also be
detected. Flow cytometry was originally used to assess cell numbers and size. It was
subsequently developed to quantify nucleic acid concentration using the absorption
and scatter of light. Mullaney et al produced the first DNA histogram with clearly
defined G0/G1, S, G2 and M phases 116. This discovery enabled the quantification of
a number of parameters on a large number of cells giving rapid and reproducible
results.
Flow cytometry depends upon the preparation of a single cell suspension,
necessitating grinding of the tissue. The DNA can then be stained, filtered to remove
clumps and syringed to break up small aggregations. The stained cell suspension is
injected into the flow cell of the flow cytometer where it is hydrodynamically
focused to pass through the interrogation point, excitation taking place in either an
enclosed quartz flow cell or in air. The cell interacts with the laser light (emitted at
488nm), scattering it in all directions; light scattered in a forward direction is related
to the size of the cell, and that at 90 degrees to the amount of refraction of its
internal structure. Analogue electrical signals are generated for each particle and
converted into digital signals for processing by the computer software to generate
parameter correlated histograms. Many different dyes can be used. In this study
propidium iodide was used: when excited at 488nm it emits light in the red spectrum
at 589nm. The intensity of the red light emitted by the excited nuclei correlates to
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the amount of DNA in the nucleus. A photomultiplier tube, which amplifies the
signal prior to converting it to a digital pulse, senses the red light. The accumulated
pulses from a sample area are then used to generate a histogram.
1.8.2.1 Flow cytometry and Barrett's oesophagus
The evolution of Barrett's mucosa to adenocarcinoma is frequently associated with
the development of large changes in the DNA content (ploidy) of the epithelial cells.
This can be detected by flow cytometry. All cells in the body, except germ cells are
diploid. In normal tissue, most of the cells are in the GO phase and are shown as a
2N peak when analysed by flow cytometry. In this situation, less than 5-10% of cells
show a 4N peak as a result of being in the S or G2 phase of cell division.
Abnormalities are identified either by an increased percentage of cells in the 4N
phase (S or G2 fraction) suggesting rapid cell division, or by the presence of one or
more aneuploid peaks, when >2.5% of the cell nuclei demonstrate abnormal DNA
content (>2N).
Flow cytometric abnormalities have been demonstrated in all grades of Barrett's
metaplasia from non-dysplastic tissue to adenocarcinoma.
In the first report in 1987, aneuploidy was found in 5.5% of normal patients, in
17.2% of patients with Barrett's, in 100% of patients with dysplastic Barrett's and in
83.3% of patients with oesophageal cancer 117 A second report in the same year
reported either aneuploidy or an increased G2 fraction in 0/18 normal patients, in
2.9% of patients with Barrett's metaplasia, in 25% of patients with indefinite or low-
grade dysplasia, and in 100% of patients with high-grade dysplasia or Barrett's
adenocarcinoma U8. In a subsequent report similar results were reported as
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indicating an association between the presence of flow cytometry abnormalities and
increasing dysplasia 119.
Rabonovitch et al showed that one or more aneuploid cell populations was
commonly identified in oesophageal adenocarcinoma 120. Of 14 patients with
Barrett's adenocarcinoma 12 had at least two aneuploid cell populations and four
patients had more than 10 aneuploid cell populations. They found a variable
concordance between grade of dysplasia and aneuploidy, showing that aneuploidy
could be found in a proportion of patients without dysplasia. Another study, which
analysed 69 biopsies obtained from 19 patients with Barrett's oesophagus,
confirmed these findings 121. Dysplasia occurred in the absence of flow cytometric
abnormalities and, conversely, the latter could be present in the absence of dysplasia.
These observations are important since they raise the possibility that flow cytometric
abnormalities may be a determinant of cancer risk independent of dysplasia or
preceding the development of histological changes. In prospective analysis, 62
patients with Barrett's oesophagus were followed up for a mean period of 34 months
66. Aneuploidy and increased G2 tetraploid fractions were found to predict
neoplastic progression. The authors showed that of 49 patients who had no
aneuploidy or increased G2 tetraploid fraction none progressed to high-grade
dysplasia or adenocarcinoma, while of 13 patients with flow cytometric
abnormalities 9 subsequently developed high-grade dysplasia or adenocarcinoma.
Flow cytometry has usually been carried out on fresh biopsy specimens. A recent
study has assessed the feasibility of performing flow cytometry on paraffin-
embedded biopsies to improve ease of analysis and to allow analysis of archival
material 122. Among the 58 specimens with Barrett's oesophagus, it was possible to
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analyse 86%. DNA aneuploidy was identified in 77% with high grade dysplasia,
16% with low-grade dysplasia, 23% of indefinite for dysplasia, and 0% without
dysplasia. This shows that routinely processed paraffin-embedded biopsies can be
used for flow-cytometric analysis and, in agreement with previous studies, shows a
close correlation between DNA aneuploidy and degree of dysplasia.
Flow cytometry has also been assessed as a prognostic indicator for patients
• 122
undergoing an oesophageal resection for a Barrett's related adenocarcinoma
Flow cytometry, was carried out on paraffin embedded specimens from 40 patients
with an adenocarcinoma in Barrett's oesophagus. Although there was no significant
correlation between DNA-ploidy, TNM-stage or histological grade of the tumour,
DNA-ploidy significantly (p=0.04) correlated with survival. Thus, DNA ploidy is an
independent prognostic factor for the survival of patients with an adenocarcinoma in
Barrett's oesophagus.
Further studies need to be performed to assess the usefulness of flow cytometric
abnormalities in predicting neoplastic progression in patients with Barrett's
oesophagus. It may also be useful in evaluating the ability of novel ablative
therapies to normalise the cell cycle
1.9.3 Cyclins
Cyclins are critically important regulators of the cell cycle. They act primarily by
activating cyclin-dependent protein kinases (CDK). Subsequent CDK mediated
phosphorylation of specific proteins drives the cycle through particular checkpoints
of the cell cycle. There are at least 11 distinct cyclin genes in the human genome that
can bind to and activate at least seven CDK's. During normal growth, different
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cyclins are expressed at specific times of the cell cycle. For example, cyclin B1
activates CDK1. It begins to accumulate at the time of cell exit from S, reaches a
maximum in G2 and breaks down in M.
D type cyclins are involved in the regulation of cell movement through G1 primarily
by activating CDK4 which then phosphorylates the retinoblastoma tumour
suppression gene protein RB. Phosphorylation of pRB releases E2F factor which
activates transcription of the components of the DNA replication machinery, thereby
committing the cell to the S phase 123.
Rearrangement, amplification, and/or increased expression of the cyclin D1 gene
have been reported in human parathyroid adenomas, B-cell lymphomas, and
squamous cell carcinomas of the head and neck. Thus, cyclin D1 may act as a
cellular oncogene. It has also been recently reported that overexpression of cyclin
Dl, similar to mutation of p53 is associated with genome instability 124
A recent study has shown that cyclin Dl and D3 in normal cell lines are restricted to
125G1 phase, whereas in tumour cell lines they are also expressed in S and G2/M
Overexpression of the cyclin Dl gene has been found in 32% of human oesophageal
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squamous cancer lines and in 64 % of oesophageal adenocarcinomas ;
Little research has examined cyclin expression in Barrett's oesophagus. Arber et al
have shown that about 46% of Barrett's oesophagus samples showed increased
nuclear expression of cyclin Dl protein compared to normal oesophageal mucosa
128. It has previously been suggested that early neoplastic progression in Barrett's
involves at least 3 types of cell cycle abnormality (1) Mobilisation of cells from the
GO phase to G1 (2) Loss of control of the Gl-S transition, (3) accumulation in G2
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129. It is possible that increased cyclin D1 expression in Barrett's may be responsible
for these events through its interaction with CDK4 and Rb6 tumour suppresser gene.
Thus, increased cyclin D1 expression may be a marker of early malignant change,
although other events have to occur for progression to a fully malignant tumour.
1.9.4 Proliferating cell nuclear antigen
Proliferating cell nuclear antigen (PCNA) is an accessory molecule for DNA
polymerase and is synthesised in the late G1 and S phases of the cell cycle. It is a
marker of cell proliferative activity and hence may be related to metastatic potential.
One study examined 93 specimens of Barrett's oesophagus for PCNA 13°. Luminal
staining occurred almost exclusively in the specialised Barrett's epithelium versus
junctional type epithelium and fundic epithelium. They concluded that PCNA
immunolocalization reveals that a high proportion of specialised epithelial cells are
proliferating which may explain the association between specialised epithelium and
malignancy in Barrett's oesophagus. Gillen et al assessed PCNA expression in
oesophageal epithelium from 70 patients with Barrett's oesophagus m. They
showed that the PCNA index of malignant tissue was significantly different from
that of benign and dysplastic specimens. PCNA indices in histologically normal
Barrett's epithelium adjacent to a tumour were significantly different from those in
normal Barrett's epithelium with no adjacent tumour. In the study of Jankowski et
al, the PCNA labelling index was higher in adenocarcinoma (25%) and in Barrett's
intestinal type mucosa with high-grade dysplasia (26%) than in intestinal type
mucosa without significant dysplasia (20%) and Barrett's gastric type mucosa (12%)
132
. However other studies show conflicting evidence. Jaskiewicz et al examined
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PCNA staining in 105 heterotopic biopsies with columnar epithelium 133. This study
showed a close similarity between dysplastic, indefinite for dysplasia and non-
dysplastic, mucosal counts. A further study assessing PCNA expression in a group
of patients with Barrett's oesophagus who, during follow-up, developed epithelial
dysplasia, confirmed this finding 134 Although there was a remarkable number of
PCNA positive cells in high grade dysplasia, there was a considerable overlap in the
number of positive cases between low grade dysplasia, indefinite and negative. They
concluded that the correlation of PCNA staining with degree of dysplasia is of
limited practical use.
1.9.5 Ki67
Ki67 is a murine monoclonal antibody that recognises a nuclear antigen that is
expressed in all phases of the cell cycle except GO and thus is a sensitive marker of
cell proliferation. Several studies have measured Ki67 in Barrett's oesophagus. One
study showed that measurement of Ki67 was able to distinguish between low and
high grade dysplasia 113. Another study found that the Ki67 labelling index was very
low in junctional or gastric type Barrett's epithelium, moderately high in intestinal
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type epithelium and very high in severe dysplastic epithelium or adenocarcinoma
1.9.6 Abnormal mucus and mucus production
Within dysplastic Barrett's epithelium, there is reduce or absent mucus production.
It has also been observed that the cytoplasmic organelles required for mucus
biosynthesis are reduced 102. Lapertosa et al demonstrated the presence of O-
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acetylated sialomucins in the goblet cells of specialised columnar epithelium
These were reduced in the mucosa close to a dysplastic area, and completely absent
in dysplastic tissue. This loss of O-acetylation suggests a more immature type of
epithelium, similar to that of foetal gut, where O-acetylation has not yet taken place.
However, as yet there are no data correlating these changes with degree of dysplasia
or risk of developing adenocarcinoma. Indeed one study has shown similar amounts
of sialomucin staining in dysplastic and non-dysplastic Barrett's oesophagus 133.
1.9.7 Growth regulatory factors
Epidermal growth factor (EGF) and transforming growth factor (TGF) synthesised
by the gastrointestinal mucosa bind to epidermal growth factor receptors and
regulate the growth and differentiation of the gastrointestinal tract. In Barrett's
oesophagus, growth factor activity was significantly higher in dysplastic mucosa,
than in non-dysplastic mucosa. 133. However there was no significant difference
between growth factor activity in mucosa showing different grades of dysplasia. Co-
expression of EGF or TGF-alpha and EGF-R is associated with autocrine growth
regulation in oesophageal carcinoma cells 137 Barrett's mucosa, particularly when
dysplastic overexpress TGF-alpha and EGF-R 136. TGF-alpha an EGF-R expression
were found to be low in junctional or gastric type Barrett's epithelium, and high in
intestinal type epithelium, Barrett's epithelium with moderate to severe dysplasia
1 IOC 1 oo
and adenocarcinoma ; ; . Although the increased expression of these growth
factors correlates with increasing dysplasia, its independent prognostic value has not
been proven by prospective studies.
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1.9.8 Chromosomal abnormalities
It has been shown that the development of Barrett's adenocarcinoma is associated
with allelic losses of 17p harbouring TP53 and 5q containing APC and MCC. Allelic
losses of 17p occur in diploid cells as early events and typically precede the
development of aneuploidy and other allelic losses during neoplastic progression in
Barrett's oesophagus 138 Allelic losses of 17p or 5q were found in aneuploid cell
populations from patients with Barrett's oesophagus who had high -grade dysplasia
or cancer 139. Allelic losses of 17p were found in 92% of Barrett's adenocarcinoma
and 5q allelic losses in 77% 140;141. it was demonstrated that 17p allelic losses
typically occurred before 5q allelic losses during neoplastic progression in Barrett's
oesophagus 138;139.
1.9.9 In vitro experiments
As described above, progression to cancer in Barrett's oesophagus occurs through an
accumulation of cell cycle and genetic abnormalities that have been described in
vivo. In order to better study neoplastic evolution in Barrett's oesophagus Palanca-
Wessel et al have established in vitro cultures from preneoplastic tissues 142. They
successfully established four long-term cultures form 39 attempts. All cultures
contained cytogenetic abnormalities and elevated flow-cytometric 4N DNA content
fractions. Molecular genetic abnormalities included 17p loss of heterozygosity and
p53 mutation in 3 of 4 cultures and 5q loss of heterozygosity in one culture.
Inactivation of p53 was statistically associated with successful long-term culture.
Such cultures may provide a premalignant in vitro system in which to test potential
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therapies for Barrett's oesophagus as well as to examine aetiological factors in
neoplastic progression.
1.10 Treatment
1.10.1 Medical and surgical therapy
By definition metaplastic epithelium has the potential to revert to normal 143.
Although both medical and surgical therapy to reduce acid reflux have been reported
to induce regression of Barrett's epithelium, these reports have been infrequent and
controversial144"148.
Malesci et al reported regression ofBarrett's oesophagus using 60mg of omeprazole
every morning for one year. Twelve of the 14 patients had normalisation of pH in
the oesophagus. The mean reduction in the length of the Barrett's was 2.4cm with
complete regression in two patients 149. One study has also demonstrated that
elimination of reflux symptoms does not ensure that acid exposure is controlled in
patients with Barrett's oesophagus 150
A randomised trial of 59 patients with Barrett's oesophagus has compared medical
treatment versus anti-reflux surgery 151. In the surgically treated group, eight of 32
patients had a decrease whilst three had an increase in the length of Barrett's
oesophagus. In the medically treated group two out of 27 patients had a decrease
whilst 11 had an increase in the length of their Barrett's oesophagus. Unfortunately,
this study has several flaws. At least eight of the 59 patients lacked intestinal
metaplasia, and the medical group received omeprazole at an unspecified dose only
10 years after initiation of the study.
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To date oesophagectomy provides the only reliable therapeutic option for patients
with high-grade dysplasia or early cancer. The high mortality rates, ranging from 4%
to 10% in a largely elderly population make this an undesirable procedure 152. The
development of minimally invasive endoscopic therapies for Barrett's oesophagus
therefore deserves prime consideration.
1.10.2 Endoscopic therapies
Several different endoscopic modalities have been used to ablate Barrett's mucosa
and potentially reduce the risk of cancer. These include Neodynium:Yttrium-
Aluminium-Garnet (Nd:YAG) laser thermal ablation, Argon Plasma Coagulation
(APC) and Photodynamic Therapy (PDT). One study reports ablation of Barrett's
oesophagus in 10 patients treated with high-dose omeprazole and endoscopic
multipolar electrocoagulation 151. The entire Barrett's oesophagus was reversed by
visual and biopsy criteria in five of these patients.
1.10.2.1 Photodynamic Therapy
PDT uses the combination of drug and light administered by dye lasers to achieve
local tissue destruction. Initially, a photosensitiser is administered intravenously, or
orally and is subsequently retained by the precancerous or malignant tissue. Such
photosensitisers are non-toxic in their natural state, but when activated by light they
become cytotoxic and cause local tissue destruction. The exact means by which this
occurs depends on the specific photosensitiser, but it usually relies on the presence
of oxygen and the formation of oxygen free radicals. Oxygen radicals are highly
reactive and destroy proteins and cell membranes.
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As light can only penetrate tissue to a depth of 10-20mm PDT compounds can only
be activated to cause tissue damage within superficial lesions. As most
photosensitisers depend on the presence of oxygen to produce their cytotoxic effect,
an adequate blood flow to the treatment area is essential.
Fourteen patients with Barrett's mucosa, with or without dysplasia, received
therapeutic treatment for the first time in 1993 69. In the largest reported series to
date Overholt and Panjehpour, described their experience in 35 patients with high-
grade dysplasia, 14 of who also had early adenocarcinoma 153. Using
dihematoporphyrin-ether, photodynamic ablation of dysplastic or malignant mucosa
was followed by healing and conversion of 75-80% of treated Barrett's mucosa to
normal squamous epithelium. Complete elimination of Barrett's epithelium was
achieved in 10(28%) patients. The major complication was stricture formation which
occurred in 60% of patients.
One of the attractions of PDT for the treatment of Barrett's oesophagus is its
technical ease of delivery, and a complete Barrett's segment can be obliterated in
one session. Unfortunately, there are some drawbacks. Dihematoporphyrinether is a
first generation photosensitiser and induces a photosensitisation of the skin, so that
phototoxic effects in skin areas exposed to light may occur in the first few weeks
after treatment. Secondly, selective ablation of the dysplastic tissues cannot be
reliably achieved without damaging deeper layers of muscular tissue resulting in
oesophageal stricture formation.
In an attempt to reduce the complication rates of mucosal ablation using PDT, 5-
aminolevulinic acid (5-ALA) has been used as the PDT agent in more recent studies.
PDT with 5-ALA is unique because the photosensitiser (protoporphyrin IX (PpIX))
38
is synthesised in vivo after administration of a precursor compound. Exogenously
administered 5-ALA results in the production of much greater levels of PpIX in the
mucosa of the gastrointestinal tract than the submucosa and muscularis, making it an
attractive agent for use in mucosal obliteration 154 In addition, skin photosensitivity
with 5-ALA lasts only a few days.
Considerable interest was been generated by a small pilot study reporting
eradication of high grade dysplasia in columnar-lined epithelium by endoscopic
photodynamic therapy using 5-ALA 155. Patients were also treated with omeprazole
40mg daily and were followed up for 26 to 44 months. Gossner et al report a larger
study of photodynamic therapy using 5-ALA in 10 patients with high grade
dysplasia and 22 with carcinoma 156. High grade dysplasia was eliminated in all 10
patients, and although large portions of the treated oesophagus were subsequently
re-epithelialised, complete eradication of Barrett's epithelium was not seen. In two
cases specialised columnar epithelium was found underlying newly formed
squamous epithelium. Early cancers were only obliterated in 17 of the 22 patients. In
particular lesions thicker than 2mm were not adequately treated by this method.
It seems that the optimum depth of penetration of PDT has not yet been achieved.
Further controlled studies need to be performed before PDT can be recommended
for routine treatment ofBarrett's oesophagus.
1.10.2.2 Thermal laser therapy
Several studies have examined the ability a variety of endoscopic laser therapies to
ablate Barrett's epithelium and permit re-epithelialisation with squamous epithelium.
The different types of laser cause different depths of tissue penetration. The
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estimated penetration of the Nd:YAG laser is 4mm whereas with Argon plasma
coagulation it is 1mm 157
A small study form Luman et al that randomly assigned eight patients with Barrett's
epithelium to acid suppression with and without Nd:YAG laser photocoagulation
found no change in the extent of Barrett's epithelium in both groups 158. It is
possible that the greater depth of tissue penetration with the Nd:YAG laser could
have destroyed the multi-potential stem cells thought to be essential in allowing re-
epithelialisation. Secondly the technique of laser therapy seems to be important. In
this study, laser therapy was applied retrogradely, starting at the gastro-oesophageal
junction and moving more proximally. Hence the ablated area remained surrounded
by columnar epithelium. Berenson et al have suggested that the best response to
laser therapy occurred when columnar epithelium was lying adjacent to squamous
epithelium 159. Sampliner et al reported regression of Barrett's epithelium after
ablation with Nd: YAG laser and acid suppression in a 76-year old man 16°.
Other unsuccessful results of laser photoablation of Barrett's epithelium have also
been described. Brand and Kauvar reported that an initial endoscopic examination
performed six weeks after treatment with Nd: YAG laser revealed no endoscopic or
histologic signs of Barrett's epithelium, but follow-up endoscopic examination 14
weeks later showed that Barrett's epithelium had reappeared despite acid
suppression with 20mg omeprazole daily 161.
One of the reasons for failure in these studies could be that medical therapy does not
prevent the reflux of duodenal contents into the oesophagus. In order to prevent this,
one study has examined the combined use of endoscopic laser ablation and anti¬
reflux surgery in 10 patients with Barrett's oesophagus 162. One to eight treatments
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with the Nd:YAG laser were required for all the intestinal metaplasia to be ablated
and for squamous epithelium but no intestinal metaplasia to appear in the biopsies.
Squamous reepithelialisation was complete in all but two patients in whom intestinal
metaplasia persisted in the gastric cardia, and remained during a mean follow-up of
26 months. In a control group of six patients who had surgery alone, the length of
intestinal metaplasia in biopsies at endoscopy remained unchanged during the mean
follow-up period of 21 months.
Barham et al used the KTP laser in 16 patients with non-dysplastic Barrett's
oesophagus all of whom were on acid suppressive therapy 156. All laser treatments
resulted in squamous regeneration confirmed endoscopically and histologically. The
number of treatments required depended on the length ofBarrett's segment. In 11 of
the patients there was evidence of squamous regeneration over remaining Barrett's
glands.
Several studies have reported encouraging results of the use of APC to ablate
columnar-lined oesophagus and facilitate squamous re-epithelialisation. In one
study, ten patients with Barrett's oesophagus received acid suppression and
treatment with APC at 2-5 week intervals. During multiple endoscopic sessions, one
to eight segments of Barrett's oesophagus ranging from 0.25cm2 to four cm2 were
treated using APC until the treated segment turned white. Thirty-eight out of 40
treatment locations partially or completely re-epithelialised with squamous tissue.
However, glandular tissue persisted beneath the squamous epithelium !59. In a more
recent study, 13 patients with Barrett's oesophagus were treated with the APC I63.
Some degree of replacement ofBarrett's lining by squamous epithelium occurred in
all patients. Success (macroscopic and histological regrowth of squamous epithelium
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in>80% of the Barrett's oesophagus) was achieved in five patients. In these patients,
there was no histological evidence of squamous epithelium overlying columnar
epithelium.
Another study has suggested complete restoration of squamous mucosa in 70% of
the 21 patients treated with APC in combination with a PPI 164 Others have
suggested that normalisation of oesophageal acid exposure is important in
preventing recurrence of Barrett's oesophagus at one year follow-up. Martin et al
treated 25 patients with Barrett's oesophagus with repeated APC and acid
suppression 165. They found that approximately one session of APC per one cm of
Barrett's mucosa was needed.
Although such endoscopic therapies are promising, it is of concern that several
studies have reported the occurrence of specialised columnar epithelium underlying
newly formed squamous epithelium. This has occurred after photodynamic therapy
156, multipolar electrocoagulation 1M, APC 159;1663 and the KTP laser 167 These
observations have raised concerns that the treatment of Barrett's epithelium may be
harmful in the long run if overlying squamous mucosa makes surveillance of
Barrett's epithelium more difficult. Furthermore unless complete eradication of
Barrett's epithelium can be reliably achieved there is still the possibility that
dysplasia would occur at a later date.
The mechanism of reepithelialisation is unclear. Biddlestone et al have examined the
histopathology of Barrett's oesophagus after treatment with acid suppression and
laser and photodynamic therapy 168. The histologic findings suggest three main
mechanisms for reepithelialisation: encroachment of adjacent squamous epithelium
at the squamo-columnar junction, extension of epithelium from the submucosal
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gland duct to form squamous islands, and squamous metaplasia within the Barrett's
columnar mucosa itself.
A further question that remains unanswered is whether cancer risk is actually
reduced in the regenerated squamous epithelium. As yet no long term randomised
study comparing untreated versus reversed Barrett's oesophagus patients has been
reported. One recent study has looked at several cancer risk biomarkers to establish
whether reversed squamous epithelium after multipolar electrocoagulation is
biologically normal and poses a lower risk 169. Using histology, ornithine
decarboxylase activity, Ki-67, PCNA, and p53 mutations they confirmed that the
reversed squamous epithelium was biologically similar to normal epithelium and
hence may not be associated with increased cancer risk.
Even if endoscopic treatment of Barrett's proves effective, the impact of treatment
on outcome still needs to be established.
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CHAPTER 2- Oesophageal cancer (A critical review of the literature)
2.1 Epidemiology
Oesophageal cancer has an estimated incidence of about 7.5 per 100,000 in the UK
and accounts for more than 3500 deaths per year 170. The incidence of squamous cell
carcinoma varies widely in different geographical areas. Areas of high incidence
include NE Iran, N. Afghanistan, S. Russia and N. China. Non-Caucasian males are
most commonly effected. Oesophageal adenocarcinoma is a disease of the Western
male. Prior to the 1970's this was a rare disease but over the past three to four
decades there even seems to have been a disturbing increase in the occurrence of
oesophageal cancer in the UK, USA and Western Europe 86"88;171.In the USA
according to data from the Surveillance, Epidemiology, and End Results (SEER)
program, this rate of increase exceeded that of any other type of cancer during the
period 1970 to 198987. Several methodological issues, including improved
specification of diagnosis in terms of anatomic site and histologic type, were
considered as possible confounding factors, but were felt unlikely to explain this
trend 87;172. The reason for the increasing frequency of oesophageal adenocarcinoma
is unclear.
2.2 Aetiology
Tobacco and alcohol abuse are associated with the development of squamous cell
cancer, but not with adenocarcinoma 173;174 The major risk factor for the
development of adenocarcinoma is the presence of the pre-malignant Barrett's
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oesophagus which is thought to be a consequence of gastro-oesophageal reflux ;
The degree of risk has been reported by several studies and varies from between 30-
125 times the normal population 59"61-69-176"178 Qne epidemiological study has
examined the use of pharmaceutical agents which relax the lower oesophageal
sphincter possibly resulting in gastro-oesophageal reflux and Barrett's oesophagus
179. Between 1957 to 1986 in the USA there has been an upward trend in the use of
such drugs purchased per capita through retail pharmacies and hospitals. This study
makes a speculative association between the increased use of drugs relaxing the
lower oesophageal sphincter and the rising incidence of oesophageal
adenocarcinoma in the USA. Obviously this hypothesis needs to be tested in a case-
control study.
There has also been speculation around the relationship between Helicobacter Pylori
(HP), and the development of Barrett's oesophagus and oesophageal
adenocarcinoma. Several studies which examined the prevalence of HP in both
gastric and oesophageal specimens from patients with Barrett's oesophagus have
been reviewed180. In a total of 360 patients, oesophageal colonisation was found in
23 .2%. Gastric Helicobacter pylori colonisation was documented in 71% of cases.
Of these 261 patients, 22% had gastric infection. This figure is similar to that
expected in the general population and does not support a role for Helicobacter
pylori in the pathogenesis of Barrett's oesophagus. Few studies have examined the
role ofHP in the progression from Barrett's oesophagus to adenocarcinoma. Quddus
et al found no evidence of HP in 19 patients with adenocarcinoma arising in
Barrett's oesophagus 181. Henihan et al found a significant association between HP
and severity of inflammation in patients with Barrett's oesophagus182. HP was
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absent in patients with adenocarcinoma and moderate to severe dysplasia. Wright et
al reported a negative correlation between HP and increasing dysplasia183. These
results are very preliminary and further prospective studies are required to elucidate
the role ofHP in the development of oesophageal adenocarcinoma.
2.3 Palliative treatments for oesophageal cancer
The prognosis of this disease is extremely poor, with a median five-year survival of
about 5% 184 Only one third of patients are suitable for curative resection at
presentation and for the remaining patients, only palliative therapy is possible.
Effective palliation of dysphagia is the goal of treatment as this is the cause of much
debility and distress. A variety of different techniques have been developed 185.
Conventional palliative procedures for advanced oesophageal cancer include
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surgery, radiotherapy, chemotherapy and surgical insertion of plastic prostheses
More recently advances in both endoscopic and radiological techniques have
enabled the development of less invasive methods of palliation, including laser
therapy and insertion of expandable metal stents.
2.3.1 Surgery
Surgical relief of dysphagia can be achieved by resection. Although the best way of
palliating dysphagia, such surgery is associated with a high morbidity, mortality and
prolonged hospital stay. Mortality rates for bypass surgery vary from 20%-30% 187"
190. One study has reported a mortality of 11% with 82% of patients having a
complete and lasting relief of dysphagia 191. Surgery is not commonly used for
palliative therapy as such figures make it difficult to justify its use in patients with
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advanced disease who have a short life expectancy and often significant comorbid
disease.
2.3.2 Radiotherapy
External beam radiotherapy (EBRT)
Radiotherapy, as compared to endoscopic therapies has the potential to inhibit local
tumour growth. Radiation may be either given by external beam or through an
intraluminal source (brachytherapy). About 50-70% of both squamous cell
carcinomas and adenocarcinomas respond to EBRT192"196. However, the relief of
dysphagia may take several weeks and the general debilitating effects following
radiotherapy may detract from any improvement in swallowing. In addition
complications such as fibrotic strictures and oesophago-respiratory fistula occur in
about 30% of patients 192"196.
Brachytherapy
Intraluminal radiotherapy was made possible by the development of the Selectron
remote control after-loading machine. The biggest advantage of brachytherapy is its
ability to provide the highest dose of radiation to the tumour whilst sparing the
• • 197 198normal tissues. It has proved to be a safe and effective method of palliation ;
Fleischman et al reported 10 patients with advanced oesophageal cancer who
underwent a short intensive course of intraluminal brachytherapy. Ninety % of the
patients had improvement in their dysphagia with an average response of 5.1
months. The only complication was mild to moderate oesophagitis in about half of
the patients one week after treatment199.
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Combined EBRT and Brachytherapy
The combination of brachytherapy with EBRT has achieved even better response
200 202
rates, although troublesome oesophagitis can occur in up to 80% of cases
Pakisch et al have reported the use of this approach in 48 patients who had either
unresectable local tumours or who were medically unfit 203. Patients underwent high
dose rate brachytherapy followed by EBRT. Of the 41 who completed the treatment
21(71%) returned to a normal diet. All patients who received more than 50 Gy of
EBRT suffered mild to moderated oesophagitis and late complications developed in
29%. In another study, 67 patients received EBRT followed by brachytherapy.
Swallowing was restored in 92% of patients 4 weeks after treatment, although half
required late dilatation for stricture formation 204 In a study of 46 patients
undergoing EBRT and brachytherapy, 76% received moderate to good palliation
compared to 52% with EBRT alone 196. In another study, 35 patients underwent
EBRT followed by low-dose-rate brachytherapy 205. At six weeks post-treatment,
90% of the group could eat solid food. Most patients were well palliated until 2-4
weeks prior to death. Severe oesophagitis requiring hospitalisation occurred in 14%
of patients, and late complications developed in 17%. Although the combination of
EBRT and brachytherapy looks promising, a randomised control trial of EBRT
alone versus EBRT and brachytherapy is needed.
2.3.3 Chemotherapy
Chemotherapy has been used as an adjuvant therapy in several studies and as a
single modality in two randomised trials 206;207. in one non-randomised trial of 33
patients receiving palliative treatment for oesophageal cancer, 23 out of 30 patients
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were dysphagia- free following chemotherapy 208. Patients with distal thoracic
tumours did significantly better than proximal and mid tumours 209. This study
reported a 56% rate of moderate to severe toxicity, and Herskovic reported a 64%
rate of severe and life-threatening acute toxicity 206. However, mortality was low
(<2%) with few late complications. When used alone chemotherapy seems to have
impressive survival figures 206, but this has to be balanced against prolonged
treatment and significant morbidity in patients with poor life expectancy.
2.3.4 Dilatation
Dilatation is rarely used alone for the palliation of malignant dysphagia due to its
short duration of effect, but it is often required to permit the delivery of other
palliative techniques. Two studies have examined the use of dilation alone. In a
study of 38 patients receiving dilation alone for palliation ofmalignant dysphagia, it
was not possible to pass a guide wire in 15% of patients and 31% of patients had no
benefit from the treatment 210. The mean dysphagia free period was 11.5 days. The
second study performed dilation at four weekly intervals in 41 patients 21 \ They
reported a good relief from dysphagia initially, but 22% of patients eventually
required intubation. The main complications of oesophageal dilation are perforation,
aspiration, and bleeding giving a complication rate of 2.5-10% 212.
2.3.5 Photodynamic Therapy
Photodynamic therapy has been used to palliate malignant dysphagia. McCaughan
reported the use of PDT for palliation of oesophageal cancer in 40 patients 213. At
one month the mean luminal diameter had increased from 6mm to 9mm.
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Complications were frequent and included stricture formation (15%), tracheo¬
esophageal fistula (7.5%), and localised third-degree burns (2.5%). It may be useful
in patients with cervical strictures and can be applied to totally obstructing cancers
213.214 pj-j-j, can ke use£j repeatecjiy ancj jn patients that have failed other modalities.
Further evaluation of its efficacy is required.
2.3.6 Laser Therapy
Endoscopic laser therapy for the palliation of oesophageal cancer was originally
described be Fleischer, in 1982 215. This procedure can be performed in an
outpatient setting under intravenous sedation. For tumour vaporisation, the Nd:YAG
laser is usually applied in the non-contact mode using a high (70-150 watts) power
settings at distance of 0.5-lcm from the tumour (Figure 2.1). The laser light is
transmitted via a flexible quartz fibre which is enclosed within a Teflon sheath. This
is passed down the biopsy channel of a standard flexible endoscope. Initial dilatation
and retrograde approach technique are favoured to minimise complications 216. Pre-
treatment dilatation is required in 20% of patients with totally obstructing tumours to
facilitate the passage of the endoscope into the stomach 216.
Luminal patency can be achieved in 90-100% of patients using the Nd: YAG laser.
However, anorexia, general debility and pain contribute to a poor quality of life.
Frequently quoted factors associated with a poor response to laser include tumour
location in the upper third of the oesophagus or the gastroesophageal junction and
the presence of a sub-mucosal tumour 217 The response to laser has also been shown
by some to decrease as stricture length increases218, but others have not supported
this219.
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Figure 2.1 Endoscopic Nd:YAG laser therapy to an oesophageal tumour
Endoscopic pictures from left to right: occluded oesophageal lumen; endoscopic
laser therapy to oesophageal tumour; luminal patency restored.
The major early complications of laser therapy are oesophageal perforation, fistula
formation, and haemorrhage. In a review of several series, the total perforation rate
was 3%, bleeding rate was 1.4%, and fistula formation within two weeks of
treatment was 2.3% 220. Perforation generally results from pre-treatment dilatation
and responds to conservative management in over 80% of cases. Haemorrhage can
be controlled with local laser photocoagulation.
The major advantages of laser therapy are its high success rate with low risk of
complications. An immediate improvement in dysphagia occurs and the treatment
can be repeated indefinitely. However regrowth of tumour into the lumen often
develops and in most series, repeated treatment is required at four to eight week
intervals 175;221. Thus, laser therapy is usually repeated on numerous occasions,
particularly in long term survivors. In most studies the duration of palliation has not
been well documented. Bourke et al evaluated dysphagia scores after treatment and
within two weeks of death217. Although 96% of patients were palliated initially, only
73% were swallowing well at the later stage. Only half of patients maintained their
initial level of palliation and 27% required stent placement. One study has even
suggested that laser therapy is effective for prolonging survival in patients with
squamous cell carcinoma of the oesophagus 222. However this was a small
retrospective study, so the results should be treated with caution.
In an attempt to increase the duration between laser treatments and to treat
extraluminal disease, external radiotherapy and brachytherapy have been added.
Laser plus brachytherapy provides good palliation and may provide a longer
aao OO /I
dysphagia free interval than historical controls treated with laser alone ;
Shmueli et al evaluated a combination of Nd:YAG laser and intraluminal
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radiotherapy in 32 patients with inoperable oesophageal carcinoma 224. Patients with
squamous cell carcinoma also received external radiotherapy. After treatment, all
patients were able to ingest a semisolid diet, although 18 patients developed
symptomatic fibrous strictures. Two thirds of patients eventually required some form
of later endoscopic intervention. It is unclear whether the addition of brachytherapy
reduced the need for repeated endoscopic intervention.
In another randomised trial 12 patients received either laser therapy alone or laser
therapy followed by the insertion of an Oesophageal Wallstent. Swallowing was
similar in both groups. The third of patients who had a short life expectancy did not
benefit from the combined therapy. In the remaining patients the dysphagia free time
was increased by a factor of two to four 225.
Although, the Nd: YAG laser has mainly been used for palliation of oesophageal
cancer, in a recent study, 9 patients with malignant dysphagia were successfully
palliated using APC 226. This technique needs further evaluation.
Nd:YAG laser therapy has therefore been established as a safe an effective
technique for palliating malignant dysphagia. However few trials have compared it
with newer methods of palliation such as insertion of expandable metallic stent.
2.3.7 Intubation
2.3.7.1 Plastic Prosthesis
Endoscopic intubation is a well-established treatment for the palliation of malignant
dysphagia. Initially, rigid plastic tubes were introduced at laparotomy, with a
mortality as high as 45% 227;228 Atkinson et al developed a technique for the
endoscopic insertion of plastic prostheses with a reduced complication rate 229;230.
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Although insertion of semi-rigid prostheses gives rapid relief of dysphagia, the
quality of swallowing is often poor and most patients are unable to consume a
normal diet after intubation 231. This seems to occur because although the outer
diameter of these tubes is relatively large, the inner lumen is relatively small. If all
232 235
complications are considered, the reported morbidity ranges from 22%-60%
Early complications include perforation (6%), haemorrhage (3.5%), aspiration
pneumonia (0-2%) and tube dislocation (15%) 220;236. Late complications include
obstruction (9.5%), dislocation (8%), and pressure necrosis (3%). In a review of
several series, hospital mortality averaged 8%220.
Despite the associated morbidity, intubation has several advantages. It can be
performed in a single session, hospital readmission may be unnecessary.
Oesophageal fistula can be sealed.
2.3.7.2 Expandable Metallic Stents
In an attempt to reduce the complications of the standard prosthesis, a new class of
expandable metallic stents has been developed. Frimberger first proposed their use
in 1983 237 (Figures 2.2, 2.3, 2.4). The theory is that an expandable metallic stent can
be restrained within a much smaller delivery system, allowing safer introduction into
the oesophagus and across the stricture. Removal of the restraining device enables
the stent to expand to a large diameter, resulting in rapid palliation of dysphagia. A
variety of different designs are available. The three most commonly used types are
the Wallstent, the Ultraflex device and various modifications of the Gianturco stent.
The Wallstent is a self-expanding, metallic-mesh stent originally designed for use in
the biliary tree. Two sizes ofWallstent are available: 20mm diameter and 110mm in
length, on an 18F delivery system, or 25mm diameter and 105mm length on a 22F
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delivery system. The middle 7cm is covered with polyurethane. The compressed
stent is arranged within three coaxially arranged shafts. The system allows the distal
50% of the stent to be released before repositioning of the stent and full deployment.
The Ultraflex mesh is an uncovered stent made of a knitted nickel-titanium alloy
(nitinol), which has thermal memory characteristics. It has a diameter of 18mm
when fully expanded and are available in three lengths (70,100 and 150mm).The
proximal end of the stent is slightly flared to improve its anchoring to the
oesophageal wall. It is compressed and encased in gelatine within a 24F plastic
sheath. After placement the stent is released by retraction of the delivery sheath.
Oesophageal fluids dissolve the gelatinous material, allowing the stent to expand.
Figure 2.2 Expandable metallic stent (Wallstent)
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Figure 2.3 Radiologically placed expandable metallic stent





Figure 2.4 Endoscopic view ofexpandable metallic stent.
The stent has expanded well providing a clear lumen within the oesophagus
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The Gianturco stent is constructed from a basic unit in which a 0.018-inch stainless
steel wire is bent in a zigzag fashion to form 2cm long segments. Multiple segments
are then sutured together to form the prostheses. The stent is covered in polyethylene
to prevent tumour ingrowth. Hooks on the external surface of the central bodies
prevent stent migration.
The first successful use of a metallic stent in oesophageal carcinoma was reported by
Domschke et al in 1990 238. Since then there have been many reports of their use,
some with long-term results. Most of these studies have been uncontrolled and are
summarised in Table 2.1. Most series report good palliation of dysphagia but also
highlight problems and limitations. In one uncontrolled study, 26 patients received
uncoated Nitinol stents 239. In one patient a broken stent strut caused a partial
stenosis, whilst three others had recurrent dysphagia due to tumour in-or
overgrowth. A second similar study in 59 patients revealed tumour in- or overgrowth
in 21(36%). 51% of patients required further intervention.
One of the earliest controlled trials compared the insertion of an uncoated metal
stent and a semi-rigid endoprosthesis in 42 patients with malignant dysphagia 240.
Although the dysphagia scores improved significantly and similarly in both groups,
there was a significantly higher rate of complications with the plastic prostheses,
including three deaths, and a longer duration of hospital stay. The recurrent
dysphagia rates were similar, with the plastic prostheses prone to migration, whilst
the metal stents were occluded either by tumour overgrowth or ingrowth. Similarly,
De Palma et al have performed a randomised trial directly comparing conventional
plastic prostheses versus expandable metal stents 241. Rates of successful stent
placement and improvement in dysphagia scores were similar in both groups, but
57
expandable stents had a significantly lower complication rate (0% vs 21%) and
procedure -related mortality (0% vs 15.8%). This is a particularly high mortality and
complication rate in the plastic stent group and may have been related to vigorous
dilatation prior to stent placement.
In a retrospective study, 38 patients who received expandable metal stents were
compared with 47 patients who received plastic stents 242. Insertion complications,
procedure-related mortality, and improvement of dysphagia were similar in both
groups. However subacute complications such as chest pain, stent migration, stent
occlusion, stent erosion and aspiration pneumonia, were found to be higher in
patients receiving expandable stents (80%) as compared with those receiving plastic
stents (60%).
In a recent randomised prospective study, 75 patients were treated with either a
Celestin tube or an uncoated Gianturco stent 243. Again, major complications were
significantly less frequent in those receiving the expandable metal stent. Previous
radiotherapy or chemotherapy predisposed to more device related injury. A second
randomised study compared the use of the Atkinson tube and the Gianturco stent for
the palliation of 31 patients with inoperable oesophageal carcinoma 244. In this study,
quality of life was assessed using the Nottingham Health Profile. This showed that
patients treated with Gianturco stents maintain their weight for longer, with
improved swallowing, appetite and quality of life when compared to those with
Atkinson tubes.
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2.3.8 Comparison of treatments
Cwikiel has made a comparison of the palliative effects on dysphagia of
radiotherapy, chemotherapy and insertion of an oesophageal stent 265. On completion
of treatment 56% of patients treated with radiotherapy, 49% of those treated with
chemotherapy, and 81% of patients treated with self-expanding metallic stent were
free from dysphagia.
The most frequent comparison of endoscopic means of palliating malignant
dysphagia has been that of laser therapy versus intubation. Two retrospective studies
have shown that adequate palliation was achieved with a high success rate by both
laser therapy and stent placement 266;267 Several prospective studies have been
performed. In one, 40 patients with malignant dysphagia were randomised to either
endoscopic intubation or laser recanulisation268. The best swallowing grade achieved
was significantly better with laser recanulisation (median 4) than with intubation
(median 3). This better palliation in the laser group was not reflected in a significant
improvement in survival. In a second non-randomised prospective study, 43 patients
treated with the Nd: YAG laser were compared with 30 patients treated by
endoscopic intubation 231 Initially patients with thoracic tumours responded equally
to either method, although those with cardia tumours were better palliated by
intubation. In patients palliated over a long period, the mean dysphagia grade for
the remainder of their lives was better in the laser group. The perforation rate was
lower in the laser group, but no treatment-related deaths occurred in either group.
One randomised study comparing laser therapy with self -expandable metallic stents
269
. In this 60 patients were treated with either covered stents (23 patients), or
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uncovered stents (19 patients), or by laser (18 patients). Both stented groups had an
improvement in dysphagia score by two points, whereas the laser group only
improved by one point. Six of the covered stents migrated compared with none in
the uncovered group, whereas the latter group had 26% tumour ingrowth. They
concluded that both types of stent had a similar efficacy but they were better than
laser therapy in palliating dysphagia. However, no data were collected regarding
quality of life.
2.3.9 Survival
Although, the main aims of palliative therapy for patients with oesophageal cancer
are improvement of dysphagia and quality of life, survival is an important
consideration. Many studies do not present their survival data; the others are
summarised in Table 2.2. In the studies comparing the use of the plastic stent with
that of the expandable metallic stent, the latter group had a tendency to live longer
240.242.243.256 simjjariy; comparing laser therapy with the use of the plastic stent,
laser treated patients had a better survival 231;268;270 There are very limited data for
the comparison of laser therapy with expandable metallic stent. In the study by
Adam et al, comparing laser therapy with both uncovered and covered stents
survival was similar in all groups 269. In another, smaller study laser treated patients
had a significant survival advantage over stented patients 271.
63
























































2.4 Health related quality of life (HRQOL) in patients with
oesophageal cancer.
Carcinoma of the oesophagus frequently presents at an advanced or disseminated
stage. Only about one third of patients present with resectable disease. For the rest,
palliative procedures may be undertaken. The 'best' palliative treatment depends on
the main aim of therapy. Relief of dysphagia and Quality of Life are now
recognised as the most important aims in the palliation ofmalignant dysphagia.
2.4.1 Health Related Quality of Life (HRQOL)
Quality of Life (QOL) is a vague term and means different things to different
people. HRQOL has developed out of recognition that only part of QOL is a
consequence of health status, but in individuals with chronic disease, ill health is a
significant contributor to QOL.
HRQOL is a difficult concept to define. One definition is 'The functional impact of
an illness, and its consequent therapy, upon the patient, as perceived by the patient'
274. There is no consensus as to what should be measured, and the literature includes
a whole range of components that could be considered. Spilker identifies four major
areas: physical status and functional abilities, psychological status and well being,
social interactions, and economic status 275. Physical status relates to a persons
ability to carry out activities of daily living, whilst the psychosocial aspects deal
with the effects of illness upon emotion and the social interaction with friends,
family, colleagues and the community. Spitzer emphasised that some psychosocial
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elements are more important that physical symptoms in patients suffering from
chronic disease 276. Ware has also suggested five inherent dimensions in HRQOL.
These are physical health, mental health, social functioning, role functioning and
general well-being 277.
2.4.2 Requirements ofmeasures
All HRQOL tools must undergo rigorous assessment before they are accepted as
valid tools for the measurement of disease outcome
Reliability
All instruments must produce the same results when used again under the same
conditions.
The test-retest reliability can be examined, although in practice it may be difficult to
distinguish measurement error from real changes in quality of life. Internal
reliability, the extent to which items addressing similar concepts agree, should also
be assessed. Inter-observer reliability also needs to be established.
Validity
The validity ofHRQOL measures is more difficult to assess because HRQOL is by
definition subjective. A crude approach is to examine face validity by asking a
variety of people whether the instruments seem to cover the full range of topics. A
more formal approach is to examine construct validity. This relates the HRQOL
instrument with other more established measures. This may require examination of
the instrument's ability to distinguish between patient groups considered to have
different health status 278. Once validity has been shown for one purpose it cannot be
assumed for all possible populations or applications.
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Sensitivity to Change
Although a HRQOL measure may be able to distinguish between patients at one
point in time, they are not necessarily as sensitive to changes in patients over time
when repeated. There are several reasons why HRQOL measures may be insensitive
to changes over time. Generic questionnaires may be insensitive to change if they
include several items that are irrelevant to the particular disease. Instruments may
include items that are static, for example patterns of social relationships. If
individuals score the minimum or maximum on a particular scale it will not be able
to detect either further deterioration or improvement respectively. Lastly, the breadth
of the categories may be too large to be sensitive to subtle changes in patients.
Appropriateness
To ensure that the quality of life measure used is the most appropriate, the health
problem and likely impact of treatments being investigated need to be carefully
considered.
Practicality
For routine use, the more detailed and comprehensive HRQOL questionnaires are
both impractical to administer and hard to process and interpret. Briefer
questionnaires may mean that important information about patients' experiences is
missed and the validity and responsiveness of shorter instruments need to be studied.
Who should measure HRQOL?
HRQOL as assessed by the patient provides a more subjective view, whereas if
assessed by a health professional a more objective view may be obtained. There is
much controversy as to whom the best person to measure HRQOL is. Slevin et al
have shown wide discrepancies between doctors' and patients' ratings of outcome in
67
• • 77Q 780
relation to many medical therapies ; . They argued against observer assessment
of another person's QOL because an individual's values and opinions cannot be
assumed. Blazeby et al have shown poor correlation between proxy (both carer and
health professional) and patient ratings of quality of life in patients with oesophageal
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cancer
2.4.3 Types ofHRQOL measurement
Quality of life instruments are generic or specific.
2.4.3.1 Generic instruments
These are a broad measure of health status and can be applied to a variety of
populations. These tools can be further subdivided into health profiles or utility
measures. The former examines various aspects of quality of life to which a score is
given. The Sickness Impact profile is such an example, and assesses the impact of
illness on daily activities and behaviour 282. The advantage of such instruments is
their ability to make health status comparisons both among patients with the same
condition and between patients with different conditions. However, they may be too
broad and fail to focus on important aspects of QOL in a particular population.
Utility ratings have been designed by economists in an attempt to assign a numerical
value to a health state. The most well known application of these is the quality-
adjusted life year 283.
There have been many attempts to develop a generic questionnaire that is easy to
administer, short, acceptable to patients, and has been fully validated.
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The Sickness Impact Profile (SIP)/Functional Limitations Profile (FLP)
The SIP assesses the impact of sickness on daily activities and behaviour, rather than
feelings and clinical reports. It consists of 136 questions not only on functioning but
also on feelings of emotional well being and social functioning. The advantages of
the SIP are that it can be either self-administered or interview based and it can be
used with chronically or acutely ill patients. It has been well tested for reliability and
validity 284;285. its limitations are its length and it can only be used with people who
regard themselves as ill. Its responsiveness to change has not been demonstrated.
The SIP has been adapted for use in the UK as the FLP, which however requires far
more testing for reliability and validity.
The Nottingham health Profile (NHP)
The NHP was developed in the UK and is based on lay perceptions of health status.
It was developed after interviews with a large number of lay people about the effects
of illness on behaviour. The NHP relates to how people feel when they are
experiencing various degrees of ill health. It was not intended to measure HRQOL
but is useful as a survey tool for measuring perceived health. It is designed to be
self-completed, contains 38 items and requires only a few minutes to complete 286. It
has been widely used to evaluate the outcomes of many therapies. It has been well
tested for validity but only partly tested for reliability and sensitivity to change.
However it has been criticised for being insensitive in its detection of low levels of
morbidity that are important both clinically and to the patients 287.
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Short Form 36(SF36)
The SF 36 was developed at the Rand Corporation in the USA for use in the Flealth
Insurance Study Experiment/Medical Outcomes Study (HIS/MOS)288. It is a short
questionnaire with 36 items within eight health scales to measure three aspects of
health- functional status, well being, and 'overall evaluation of health'. The UK
version of the SF-36 has been slightly modified from the original US version. The
validity and reliability of the SF36 had originally been confirmed in the United
States 289. Further studies on large UK populations have confirmed it to be
acceptable to patients, internally consistent, and a valid measure of the health status
of a wide range of patients 290;291. However, Garrett et al also recommend that it be
used alongside a more disease specific questionnaire in order to measure many
aspects of patient outcome. Ware et al reviewed the testing of the SF36 and found
that it had a good validity and was more sensitive to changes in health than the NHP
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. The SF-36 was able to discriminate between groups with differing degrees of
physical disability. They also reported the results of a factor analysis, which
provided strong evidence for the conceptualisation of health underlying the SF36.
The length of the SIP precludes its use in patients with oesophageal cancer and the
NHP is relatively insensitive at low levels of morbidity. The SF36 provides a good
measure of health status amongst a wide range of patients and was chosen as the
most appropriate generic test for measurement of HRQOL in patients with
oesophageal cancer.
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2.4.3.2 Disease specific instruments in Oesophageal Cancer
These are designed for specific populations or conditions and focus on particular
areas relevant to the group. Such questions are more understandable to the clinician,
but cannot be applied in other settings.
The measurement of quality of life in patients with oesophageal cancer has been a
neglected area. A recent review using Medline identified only 51 of 7569 references
on oesophageal neoplasm that considered quality of life 293. Of these only three used
documented QOL instruments with appropriate statistical testing 270;294;295. Most of
the other studies used a dysphagia score as a measure of QOL with or without a
simple measure of performance status. The study concluded that there was currently
(1994) no well validated instrument for measurement of QOL in patients with
oesophageal carcinoma.
Carcinoma of the oesophagus often presents with dysphagia, and swallowing
difficulty is one of the most distressing and debilitating symptoms for the rest of the
patients' life. Although the majority of studies assessing palliative therapies have not
included a measure of quality of life, most have included a dysphagia score.
However, it seems that improvement in dysphagia does not necessarily correlate
with an improvement in quality of life. One study was specifically designed to
measure quality of life in 59 patients following treatment for oesophageal carcinoma
using the EORTC QLQ-C30 questionnaire 296. This showed no correlation between
dysphagia grade and various scales ofQOL.
Other studies have achieved different conclusions. Loizou et al compared the effect
of laser therapy and endoscopic intubation on the palliation of malignant dysphagia
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294. Two quality of life measurements were used, the Quality of Life Index and a
Linear Analogue Self-Assessment. Although there was poor compliance with the
questionnaires (52%), they reported a significant correlation between dysphagia
score and both quality of life scales. They also found that although the palliative
treatments initially resulted in an improved quality of life, this worsened appreciably
as the patient's condition deteriorated during the terminal phase of disease. One of
the main reasons for poor compliance was given as comprehension difficulties and
the significant time required completing both questionnaires. In another study, Barr
et al randomised patients with advanced disease to receive laser therapy only or
initial laser therapy followed by endoscopic intubation 270. The same Quality of Life
measurements as Loizou et al were used. Spearman's rank correlation between these
measurements and the results of a daily dysphagia diary kept by the patients were
significant at the 0.005 value, but they were modest in magnitude; 0.27 with the
Linear Analogue Scale and 0.43 with the Quality ofLife Index.
O'Hanlon et al have examined Quality of Life in 69 patients undergoing treatment
for oesophageal cancer using the Rotterdam Symptom Checklist, a dysphagia score
and an activities of daily living questionnaire to assess the impact of therapeutic
intervention to changing quality of life 297. They showed that these instruments were
able to discriminate between patients undergoing surgery and those undergoing
palliative therapy at presentation. Both groups reported an improvement in
dysphagia scores following therapy, whereas there was only an improvement in two
parameters of the daily living questionnaire in the surgical group and in no
parameter in the palliative group.
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Several cancer specific instruments have been developed. One of the oldest
instruments is the Karnofsky Performance Scale, which measures physical
performance and dependency 298. It was originally designed to assess palliative
treatments for patients with lung cancer and consists of a simple scale from 1 to 100.
Although easy to administer this scale is fundamentally flawed in being physician
assessed and by not measuring the broader aspects of quality of life such as social
and emotional well-being 299"301.
Spitzer's Quality of Life Index (QL) was developed for use by physicians in relation
to cancer and chronically ill patients 302. Prior to its development Spitzer et al
attempted to identify the components of quality of life by questioning lay people as
well as health professionals. This resulted in the inclusion of five dimensions in the
final questionnaire: activities of daily living, occupation, perception of health,
support, and outlook on life. Again this is a physician administered questionnaire
and suffers from a lack of correlation with patients' scores 303. It has also been
criticised for its failure to sample adequately different dimensions of quality of life
relevant to clinical trials 304
The Functional Living Index-Cancer (FLIC) was designed for use on a wide variety
of cancer patients 305. This is self-administered and well-validated, but is long and
lacks adequate specificity for clinical trials.
A number of specific instruments are relevant to patients with oesophageal cancer.
Patients undergoing gastric surgery, particularly for peptic ulcer disease have been
assessed using the Visick Scale 306. However, this is physician administered and may
be too subjective to represent the patient's true feelings. Also, as it has not been
designed or validated for use with oesophageal cancer patients, it may miss areas of
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concern. Another scale has been developed to examine quality of life after surgery
for gastric cancer 307. This correlates well with both the Visick and Quality of Life
Index of Spitzer.
The European Organisation of Research on Treatment of Cancer Quality of Life
Questionnaire (EORTC-QLQ) is a generic instrument designed for international
clinical oncology trials 308. It is a modular system that is self-administered. The basic
questionnaire considers physical concerns, functional ability, emotional and family
well being, treatment satisfaction, and social and occupational functioning. Its use in
patients with a variety of different cancers has been reported 309;310. More recently
the use of the core questionnaire has been assessed in oesophageal cancer patients
296. The findings from this study led to the development of the oesophageal module
(OES-24) to be used in addition to the core questionnaire 31 \ This includes a
dysphagia score and other quality of life questions specifically related to patients
with oesophageal cancer. It aims to improve the detection of even small differences
between different therapies.
2.4.3.3 Measures of psychological well-being
Several scales of psychological well being, particularly those designed to diagnose
the common psychiatric conditions of anxiety and depression have been developed.
To assess psychological morbidity in patients with physical diseases self-reported
feelings of anxiety and depression and behaviour are used.
The Hamilton Depression Scale (HDS)
This is a widely used scale, which assesses both cognitive and behavioural
components of depression, particularly through somatic aspects 312. This scale
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cannot be used to make a diagnosis of depression, but can be used to measure
severity once the diagnosis has been made. It has good validity and reliability.
Although this scale is popular, its reliance on measurement of somatic problems
could cause confusion when used in individuals with physical disease.
The Beck Depression Inventory (BDI)
• 313
This scale was designed by Beck et al in 1961 specifically to examine depression
Like the HDS it can only be used to assess the severity of depression once the
diagnosis has been made. It was developed by measuring attitudes and symptoms in
two groups of depressed patients who were undergoing psychotherapy. Several
studies have reported its validity and reliability, although most of the testing has
been carried out on psychiatric patients rather than those with physical illness. Beck
et al published a comprehensive review of the literature on the reliability and
validity of the scale 314 This review also shows the scale to correlate well with the
HDS and discriminate between depression and anxiety.
The Symptoms ofAnxiety and Depression Scale (SAD)
SAD was developed in 1976 and assesses anxiety and depression by concentrating
on recent symptoms 315. This scale has been developed mainly for use in the elderly.
Little work has been published regarding its validity and reliability, and Bowling
suggests that far more work is required before it can be generally recommended 316.
Hospital Anxiety and Depression Scale (HAD)
The HAD Scale was developed to detect states of anxiety and depression within a
hospital setting 317 Its aim was to design a scale to measure mood without
interference from physical illness and one to distinguish anxiety form depression.
The HAD scale consists of 14 items on two scales. Individual items are scored from
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0-3, the higher scores indicating more psychological distress. HAD depression
ratings of 7 or less were considered to be non-cases; scores of 8-10 were considered
doubtful cases and scores of 11+, definite cases.
The authors purposely excluded all items related to both emotional and physical
disorder, and questions were based solely on the psychological symptoms of
neurosis. Question eight 'I feel as if I am slowed down' can be criticised for being
unable to make this distinction between mood and physical health. Scores were not
affected by the presence of physical illness, making the HAD scale attractive for
clinical research. Although the authors present it as a valid and reliable instrument,
Bowling indicates that this was only on the basis of 100 patients and suggests that
much more work must be carried out before its performance can be judged 316.
None of these scales have been used to measure psychological and psychiatric
morbidity in patients with oesophageal cancer. The HDS is unsuitable for use in this
population due to the high number of items measuring somatic problems. The BDI
although it has a high reliability has been used mainly in psychiatric populations.
Although the majority of patients with oesophageal cancer are elderly, the SAD
questionnaire still lacks good validity and reliability testing. Although the HAD
scale also requires further testing, it seems the most appropriate tool to use in a
group of patients with oesophageal cancer.
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PART TWO: THE STUDIES
CHAPTER THREE-Treatment ofBarrett's oesophagus
3.1 Introduction
As stated in chapter one, carcinogenesis in Barrett's oesophagus proceeds through a
series of genetic alterations that activate oncogenes and disable tumour -suppressor
genes. Proliferation associated antigens Ki67 and PCNA are increased in the
columnar-cell lined oesophagus; 113;131 and DNA content flow cytometry has shown
that neoplastic progression is associated with cell cycle abnormalities 66. The
evolution from a normal cell to a malignant cell is frequently associated with a
process of genetic instability that produces large changes in the DNA content
(ploidy) of the cell. In addition, allelic deletions ofmultiple tumour suppressor genes
1 TO 1 TQ
have been demonstrated ; . Of these, TP53 gene mutations and p53 protein over-
expression are early events in the malignant transformation.
Both medical and surgical therapy designed to reduce acid reflux have been reported
to reduce regression of Barrett's epithelium, but as stated in chapter one, reports
have been infrequent and controversial 145;148. Considerable interest has been
generated by a small study reporting eradication of high grade dysplasia in
columnar-lined epithelium by endoscopic photodynamic therapy using pulsed dye
laser and a photosensitising agent 155. Laser equipment is expensive; endoscopic
APC is a new technology offering safe tissue ablation at a much lower cost. The
equipment combines argon gas with a monopolar power source. The electrode in the
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argon channel of the applicator is connected to an electrosurgical generator. The
applicator ionises the argon gas where it remains ionised approximately 2-10mm
distal to the tip of the applicator. Ionised Argon gas is electrically conductive. This
allows the current to flow between the applicator and the tissue. Current density
upon arrival at the tissue surface causes coagulation. The application of the energy
to the tissue surface is uniform and contact free. No photosensitiser is needed.
Two studies have reported encouraging results of the use of APC to ablate
columnar-lined oesophagus and facilitate squamous re-epithelisation 159;163. No
study however has addressed the question of whether the multistep neoplastic
progression is halted by ablation therapy, or whether temporary regenerating
squamous epithelium simply covers rather than replaces the metaplastic epithelium.
This study examines the ability of APC to reverse Barrett's oesophagus and to
assess if this is associated with improvement in DNA aneuploidy, normalisation of
cell cycle and abolition of p53 protein immunostaining.
3.2 Methods
3.2.1 Patient details
Patients identified with Barrett's oesophagus at routine endoscopy were considered
for this study. Each patient had columnar-lined oesophagus with specialised
intestinal metaplasia extending at least 2cm above the gastro-oesophageal junction.
Patients gave informed consent. They were excluded if they had an oesophageal
stricture or ulcer, were unwilling to take a proton pump inhibitor, had cardiovascular




All patients were commenced or continued on a high dose of a proton-pump
inhibitor (either omeprazole 40mg or lanzoprazole 30mg daily).
Endoscopy was undertaken under intravenous midazolam (2-7.5mg, Roche Ltd) and
pethidine_(25-75mg) sedation. At initial endoscopy the upper border of the
columnar-lined epithelium was defined and tattooed with India ink. Two mis of
India ink were injected into the mucosa using a standard 23 Gauge injection needle
(Variject, Microvasive, Boston Scientific Corporation) at 12 O'clock at the squamo-
columnar junction with the endoscope in neutral and the buttons forward (Figure
3 .1). Two photographs were taken of the oesophagus, using the same magnification
each time. In the case of circumferential Barrett's, quadrantic biopsies were taken
from proximal, mid and distal columnar lined epithelium using keymed 37K biopsy
forceps (Keymed Ltd, Southend on Sea, UK). These biopsies were stored in
formalin and sections were taken for histology and p53 immunostaining. Three
biopsies from the mid level of each half of the oesophagus were taken and stored in
tin foil at -20° c for flow cytometry analysis.
For circumferential Barrett's half of the columnar epithelium was then treated with
APC (APC 300 ERBE, Eleckromedizin GmbH, Tubingen). The applicator was
passed down the biopsy channel of the endoscope and the APC set on 50W.
Coagulation treatment was commenced at the squamo-columnar junction (proximal).
The aim was to ablate this junction and to create an appearance of closely spaced
'burnt white spots' (Figure 3.2). The half not treated served as an internal control to
assess the effects of acid suppression. This internal control was selected to limit the
number of patients in the study and to obviate matching variables.
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Figure 3.1 Tattooing of the oesophagus with India Ink
Endoscopic picture showing blue staining of the oesophagus at 12 o'clock at the
squamo-columnar junction.
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Figure 3.2 APC treatment to half the oesophagus in Barrett's oesophagus




Re-endoscopy was carried out at two and six months. Patients were asked about
their symptoms of heartburn and dysphagia the week prior to endoscopy. At each of
these endoscopies further photographs and multiple biopsies were taken as
previously described.
3.2.4 Histopathology
All biopsies were examined by a single pathologist (Dr M Maclntyre) who was
blinded to the labelling of the biopsies and to the side of the oesophagus treated with
argon-beam coagulation.
3.2.5 p53 Immunohistochemistry
3.2.5.1 Principal of method
Non-specific antibody interaction is blocked by treating the sections with diluted
normal serum of the host producing the secondary antibody. Monoclonal antibody
against p53 is then placed into contact with the tissue and allowed to react.
Secondary antibody, which is directed against the bound monoclonal antibody, is
then placed on the tissue section and allowed to react. Finally Streptavidin-Biotin
Peroxidase is added and this binds to the biotinylated secondary antibody. The
process is then visualised histochemically by the reaction of peroxidase with its
substrate, diaminobenzidene.
3.2.5.2 Apparatus
1. Square glass dishes
2.Funnel and filter paper (Whatman)
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3.Pipettes and disposable tips (Socorex; Finnipipette (Labsystems); Pasteur pipettes
(Copan Italia)
4.Measuring cylinders
5.Staining dish and rack
6.Staning tray




11.Stirrer (Janke and Kunkerl IKA-Labortechnik)
12.Timer
13.Fume Cupboard (WS-6 Downflow Workstation Labcaire)
14.Cover slips (22x22mm)
3.2.5.3 Solutions
A. Reagents, Chemicals, Serum and Antibodies
l .Tris analar (BDH)
3.Histoclear (BS &S Scotland Ltd)
4.Industrial Methylated Spirit (IMS99)
5.Methanol (Rathburn Chemicals Ltd)
6.6% Hydrogen peroxide (Hilcross Pharmaceuticals)





11. Lithium Carbonate (BDH)
12. Rabbit serum (SAPU)
13.Monoclonal p53 protein 1801 (Novacastra)




1.0.5M Tris buffer pH 7.6
Dissolve 60.72gms of Tris analar in 500mls ofDistilled Water. Adjust pHto 7.6
with IN Hydrochloric Acid and make up volume to 1 Litre.
2.0.1M Citrate buffer
Dissolve 2. lgms of citric acid monohydrate in 900mls of distilled water and adjust
pH to 6.0 with 2MNa OH (approximately 13 ml). Make up to 1000ml with water.
3.70% IMS 99
Add 700mls of IMS99 to 300mls ofwater
C.Working Solutions
1. 0.005M Tris buffered saline pH 7.6 (TBS)
Dilute 0.5M Tris buffer 1/100 with 0.9% sodium chloride
2.0.01 Citrate buffer
Dilute 0.1M Citrate buffer 1/10 with water
3. 0.5% Hydrogen peroxide in methanol
Add 25mls of 6% hydrogen peroxide to 275mls ofmethanol
4.1% acid alcohol
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Add 10 mis of concentrated Hydrochloric acid to 990mls of 70% IMS99.
3.Normal Rabbit serum (NRS/TBS)
Filter normal rabbit serum and dilute 1:10 with TBS 0.005M
4. Antibody dilutions
a.p53 1/40 in NRS/TBS (primary antibody)
b.Biotinylated Rabbit anti Mouse 1/500 in NRS/TBS (secondary antibody)(RAM)
c.Sreptavidin-biotin-peroxidase complex (ABC)
A Streptavidin 1 pi




1.0.05M Tris ph7.6 lOmls
2.Diaminobenzidine lOmg
3.Imidazole 1 flake
4.6% Hydrogen peroxidase 60pl
Prepare fresh
6. Prepare two sets of square glass dishes with contents as below
















Formalin fixed biopsies were processed by standard histological techniques,
embedded in wax and sectioned. Three sections from each biopsy were taken for
p53 immunostaining. One section was reserved and one section from the remaining
pair was labelled NPA (No Primary Antigen). This provided a homologous negative
control in each experiment; a positive control was taken from breast tissue. The
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slides were placed in the staining racks and placed in the glass dish containing
Histoclear overnight to ensure adequate dewaxing. The next morning they were
placed sequentially into the two glass dishes containing 100% alcohol for 10
minutes each. Finally they were moved into the dish containing 0.5% hydrogen
peroxide in methanol for a further 10 minutes and subsequently washed in running
tap water.
B. High temperature antigen retrieval
One and a half litres of 0.01M Citrate buffer were placed into the pressure cooker.
The lid was placed over loosely and the solution gently heated over a Bunsen burner
until gently boiling. The rack with the sections was placed into the buffer and the lid
closed tightly. Heating was continued until there was a continuous flow of steam
from the pressure valve and continued for a further minute. After one minute, the
pressure cooker was removed from the heat and placed under a running tap. The
steam was gradually released and the lid then removed. The sections were placed
into cold water and rinsed for five minutes and then rinsed for a further five minutes
in TBS.
C. Antibody staining
The slides were removed from the rack and a circle drawn around each section with
a PAP pen to form a reservoir for the antibody solution. Each slide was placed on
the staining tray and each section was covered completely with NRS for 10 minutes.
Sections labelled NPA were left covered with NRS for a further 30 minutes. All
other sections had excess serum removed and replaced with the primary antibody
(p53) for 30 minutes. At this stage all slides were replaced in the staining rack and
rinsed in TBS for ten minutes, replacing the solution after five minutes. Excess TBS
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was removed from the slides, which were again placed on the staining tray and
covered with the secondary antibody (RAM) for another 30 minutes. The slides were
washed in TBS for a further ten minutes, as before, then excess TBS removed and
replaced with the tertiary antibody (ABC) for a further 30 minutes.
D. Development of peroxidase activity with DAB
After another two five minute rinses in TBS, the slides were placed on the staining
racks which had been placed in the fume cupboard. Each section was covered with
DAB for exactly 10 minutes. Excess DAB was removed from each slide and
collected in a waste bottle, which was subsequently treated with Presept tablets. The
slides were placed in the staining rack and washed in running tap water for 10
minutes.
E. Staining with Haemotoxylin
The sections in the staining rack were passed sequentially through the glass dishes
arranged for haemotoxylin staining. Then they were placed into haemotoxylin for 1
minute, washed in running tap water for 15 seconds, dipped twice into l%acid
alcohol, washed in running tap water for 15 seconds and placed into saturated
aqueous lithium carbonate until blue. Following this they were again washed in
running tap water for 1 minute, placed into 70% alcohol for 5 minutes, placed into
the two dishes of 100% alcohol for 5 minutes each, and then into the two dishes of
Histoclear each for 5 minutes. Finally the sections were placed into Xylene.
F. Coverslipping sections
The coverslips were carefully cleaned and then placed on a clean piece of tissue. A
streak ofDPX was placed over the coverslip using the glass rod, of adequate size to
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cover the stained section. The section was removed from Xylene and with a tissue
the back of the slide carefully dried with a tissue. The section was carefully lowered
onto the coverslip and gentle pressure was applied to spread the DPX. Any air
bubbles were removed by applying gentle pressure to the coverslip. The
coverslipped sections were left to dry overnight.
3.2.6 Flow cytometry
3.2.6.1 Principal ofmethod
Propidium Iodide was used to bind to the DNA. It intercalates into double-stranded
nucleic acids, and is excited by the 488nm line of an argon-ion laser and fluoresces
red. Because viable cells exclude it, cells were permeabilized before adding the dye.
It also binds to double-stranded RNA, which was deactivated first by treatment with
RNase. As the instrument alignment is critical for DNA measurement it was checked









1 .Propidium Iodide (PI)
25mg PI in lOmls Isoton
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2-5(j.1 in 300|il for viability
2.TRITON
lml of concentrated PI-2.5mg/ml into 5% TRITON X 100.




A. Preparation of Samples
Samples were thawed and processed immediately. They were ground over a wire
mesh sieve to disaggregate the tissue and suspended in Eales solution. The samples
were spun in the centrifuge at 2000rpm for 5 minutes. The supernatant was taken off
and they were resuspended to 500pl in Eales solution. 125pl of PI Triton (1/10) and
lmg (i.e. lOOpl) Rnase was added to the samples.
B. Running of Samples
Samples were analysed using a FAX machine until 10,000 cells had been counted.
3.3 Statistical analysis
Mann Whitney and Chi-squared tests were used as appropriate.
3.4 Results
3.4.1 Complications
Two patients experienced mild retrosternal chest pain following the initial APC
treatment. This was self-limiting and required no specific treatment.
3.4.2 Endoscopist's Description
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The endoscopist described the extent of the Barrett's oesophagus during each
endoscopy. Although, the oesophagus had been tattooed at 12 o clock, the ink mark
could not be visualised at the two month follow up. (Figures 3.3 and 3.4 and Table
3.1).
Figure 3.3 Patient One. Endoscopic pictures at baseline (above) and 6/12 (below)
showing obliteration of tongue ofBarrett's at 5 o'clock.
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Figure 3.4 Patient Six. Endoscopic pictures at baseline (above) and 6/12(below)




























































































The number of biopsies from each patient exhibiting intestinal metaplasia or
squamous epithelium were counted. Other histological diagnoses such as fiindal,
cardiac or junctional epithelium were not considered. Biopsies containing both
intestinal metaplasia and squamous epithelium were classified as squamous
epithelium. Where biopsies revealed squamous epithelium overlying intestinal
metaplasia these were classified as "squamous epithelium". Findings in treated and
untreated sides of the oesophagus are shown in Tables 3.2 & 3.4. Two further
analyses are also shown. All the biopsies from the treated and untreated sides are
then considered together and finally only the most proximal biopsies are analysed
(Tables 3.3 & 3.5). There was a statistically significant difference in the proportion
of proximal biopsies showing intestinal metaplasia at six months as compared to
baseline. There was a also a significant increase in the number of biopsies from the
treated side showing squamous epithelium at both two and six months as compared
to baseline. This comparison was not significantly different for untreated side.
Two patients (patients 10 and 11) had low grade dysplasia within pre-treatment
biopsies. This was not observed in biopsies taken at two months. Histopathology
identified three patients with squamous epithelium overlying intestinal metaplasia,
following treatment with APC (Figure 3.5). In one patient this became apparent after
six months; in the second patient it was seen at two months but was not present at
six months; and in the third patient buried glands were seen at two months, further
follow-up not being available.
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Figure 3.5 Intestinal metaplasia buried underneath squamous epithelium following
APC treatment (x25)
3.4.4 p53 Staining
All the biopsies were examined by two blinded observers (H.J Dallal and A.
Smakov). They were in agreement over the broad distinction between negative and
positive biopsies, on the basis of nuclear staining. All the positive controls were
strongly positive and the negative controls were all negative (Figures 3.6-3.9).
Subsequently the staining was graded by a single observer (A. Smakov), into
strongly positive, positive or weakly positive. The number of p53 positive biopsies,
regardless of staining grade and histology, for the untreated and treated sides of the
oesophagus was analysed (Table 3.6). The total number of strongly staining biopsies
was also considered (Table 3.7)
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Figure 3.6 Nuclear p53 staining in specialised intestinal metaplasia (x25)
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Figure 3.8 Perinuclear p53 staining in specialised intestinal metaplasia (x25)
Figure 3.9 Apical p53 staining of gland buried underneath squamous epithelium



































































































Table 3.7 p53 Number of strongly positive staining biopsies per patient.
ALL BIOPSIES
PATIENT NO. BASELINE 2/12 6/12
ONE 1 0 0
TWO 0 0 0
THREE 3 0 0
FOUR 0 1 0
FIVE 0 0 0
SIX 0 0 0
SEVEN 0 0 0
EIGHT 0 0 0




TOTAL 4 1 0
3.4.5 Flow cytometry
All cell populations analysed were diploid (Figure 3.10) Repeats were performed on
the duplicate biopsies when flow cytometry had revealed too few cells present or
excessive interference. In these cases the repeated results are reported here. The
percentage of cells from each biopsy in the S and GO/1 phases are shown (Table 3.8
and 3.9).
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Figure 3.10 Flow Cytometry-Diploid population
32
3.4.6 Patient Eleven
One patient (patient eleven) presented with dysphagia prior to his six month follow
up. Endoscopy showed a stricture at the gastro-oesophageal junction and histology
confirmed this to be an adenocarcinoma. Tables 3.10 & 3.11 detail this patient's
histology, p53 staining and flow cytometry at baseline and two month follow-up.
The treated side of the oesophagus is shown in bold.
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Treatment ofCLO with APC appears to be a safe treatment with only two of twelve
patients experiencing self-limiting retrosternal chest pain following therapy.
The endoscopist's description subjectively reported an improvement in the
appearance of the treated Barrett's oesophagus in all patients, and this was
confirmed by comparison of the endoscopic photographs.
There was a trend for an increase in the number of squamous biopsies and a decrease
in the number of biopsies showing intestinal metaplasia in the treated side as
compared to the untreated side. If both sides are considered together, negating the
internal control, there is no change in the number of biopsies showing intestinal
metaplasia, but a trend for an increase in the number of squamous biopsies.
Considering only the most proximal biopsies, there was again a trend for an increase
in the number of squamous biopsies and a decrease in biopsies showing intestinal
metaplasia.
One of the problems inherent in using an internal control is the orientation of the
biopsies. The tattooing was not visible at two months and it was difficult to judge
accurately which was the treated and which was the untreated sides. We
endeavoured to overcome this problem by analysing all the biopsies together, thus
negating the internal control but permitting an overall view of changes in the
histology. Proximal biopsies were separated out to exclude the distal biopsies which
may represent areas of the oesophagus which had been inadequately treated with
APC.
Intestinal metaplasia is a patchy finding in an area ofBarrett's oesophagus. It is also
possible that as it is a dynamic process, it may also change with time. These
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problems introduce a sampling error into the results and also imply that the internal
control may not be entirely static.
One of the most clinically relevant finding in the study is the discrepancy between
the endoscopist's assessment of squamous reepithelialisation and the histologic
findings in biopsy samples from these areas. This probably reflects the inherent
inaccuracy of targeting the biopsy samples and the relative insensitivity of
endoscopy in identifying epithelial type. This discrepancy between endoscopic
appearance and histology also makes it difficult to assess the effectiveness of APC.
The finding ofburied glands raises practical points with regard to the biopsy of these
patients and histological interpretation of such biopsy samples. Histological
confirmation of squamous re-epithelialisation is essential, and biopsy samples taken
for this purpose must include underlying lamina propria and must not merely consist
of free superficial strips of squamous epithelium because any underlying residual
glandular mucosa would go undetected in such specimens.
Logically, it would seem that if the number of Barrett's glands present can be
significantly reduced then the risk of cancer should also be reduced. This may be an
over simplistic approach. It is possible that unless complete eradication of Barrett's
epithelium can be reliably achieved the potential for neoplastic transformation in the
remaining glands could occur.
Partial regression of Barrett's oesophagus is probably an inadequate end point when
considering the efficacy of treatment of this condition in terms of preventing
neoplastic progression. Sampliner et al report a case which seems to confirm this
• 318
view . In this report a patient with high-grade dysplasia within Barrett's
oesophagus showed extensive squamous reepithelialisation after treatment with a
113
fundoplication and a high dose PPI. A subsequent oesophagogastrectomy was
performed. Histology from the resected specimen showed two foci of intramucosal
carcinoma within overlying squamous epithelium.
In this study no patient showed complete or even extensive squamous re-
epithelialisation after one treatment with APC. It may be possible to achieve this
with multiple treatments with APC and this should be an area for future research.
Laethem et al reported their experience of multiple APC sessions in 31 patients with
Barrett's oesophagus 319. Complete eradication of Barrett's mucosa was only
confirmed histologically in 61% of patients. At one year 47% of these patients had
relapsing islands of intestinal metaplasia. It should also be remembered that APC is
a difficult and time consuming therapeutic procedure and there are considerable
practical implications if this technique is to be used outwith clinical trials to treat
patients with CLO on a routine basis.
The aim of CLO ablation is to reduce the risk of development of oesophageal
cancer. Even if it is possible to achieve complete re-epethelialisation of CLO the
effect of this on the cancer risk will remain unknown until such treated patients have
been followed-up for many years. Long-term follow-up will also permit assessment
of the stability of the reepithelialisation or if there is a tendency for the CLO to re¬
occur with time.
Of great concern is patient number eleven who developed an oesophageal
adenocarcinoma between his two and six month follow- up. His histology initially
showed three out of eight biopsies with intestinal metaplasia with low grade
dysplasia. At two month follow up this was no longer apparent. One biopsy initially
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and two biopsies subsequently were weakly staining for p53. This was assumed to
be of dubious significance as the staining was only weak. Flow cytometry if
anything showed an improvement in the stability of the cell cycle at follow up.
In this small number of patients, only two of whom had low grade dysplasia, there
were only a few biopsies that were staining positively for p53. These biopsies
represented two out of the twelve patients (16%) with at least one strongly positive
biopsy at baseline. This reflects the current literature which reports positive p53
staining in 0-15% of patients with intestinal metaplasia or low grade dysplasia
io9.iii.ii3 £ven jf ap tke p0Sitive biopsies are considered (regardless of grade) these
are too few to reach any conclusion of the effect of APC on p53 staining. Certainly,
there does not appear to be any adverse effect on p53 staining.
No aneuploid cell populations were seen. This contrasts of 2.9-17.2% of aneuploidy
in intestinal metaplasia reported elsewhere 117;118. This possibly reflects the small
number of patients used in this study. No overall change was present in either the S
or GO/1 phase. Certainly there was no adverse effect ofAPC on the cell cycle.
This study has emphasised many of the practical difficulties in studies of endoscopic
therapies for Barrett's oesophagus. Although treatment with APC is safe, the results
of this study are disappointing. No patient showed extensive squamous re-
epithelialisation, three showed buried glands, and one developed a carcinoma after a
single treatment of APC. Further studies which assess long term cancer risk in
patients treated with multiple applications of APC are required before it could be
recommended outside experimental trials.
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CHAPTER 4- Palliative treatment of oesophageal cancer
4.1 Introduction
Most patients who present with malignant oesophageal obstruction have irresectable
disease, but require palliative treatment of dysphagia. A range of approaches
including intubation with plastic 234, or expandable metal stents 240, Nd: YAG laser
n 1 f A 1 O | Q^T A/IO
, photodynamic therapy , brachytherapy , chemoradiation and palliative
surgery are available, but none is ideal. Furthermore, there is often little relationship
between relief of dysphagia and improved quality of life 296, probably because most
patients have advanced disease, which results in pain, cachexia and general
inanition.
Previous trials have shown that intubation with expandable stents is superior to
stenting with plastic prosthesis 241. It has also been shown that Nd: YAG laser
treatment is superior to intubation with plastic stents 268. One study comparing
expandable metallic stents with laser therapy show that stent placement provided
significantly better palliation of dysphagia, but provided no details on quality of life
269
In the current study dysphagia, quality of life and cost were compared in a




This was a prospective randomised trial in which patients with irresectable
oesophageal cancer were randomised using sealed envelopes to laser therapy or
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insertion of an expandable metallic stent. Dysphagia, Quality of Life scores, cost,
complications and survival were the important end points.
4.2.2 Patient Details
Fifty-two patients referred for palliative treatment of dysphagia due to oesophago-
gastric cancer were recruited. All had been assessed by both a specialist
gastroenterologist and dedicated upper gastrointestinal surgeon who agreed that
resectional surgery was inappropriate because of locally advanced disease (5 laser
and 6 stent), lymph node involvement (4 laser and 3 stent), distant metastases (10
laser and 10 stent), or severe co-morbidity (6 laser and 8 stent).
All patients underwent upper gastrointestinal endoscopy with biopsy of the tumour,
barium swallow to define the site and length of the stricture and computerised
tomography of abdomen and thorax to define tumour size, local invasion and the
presence ofmetastases.
4.2.3 Dysphagia
Dysphagia was scored on a scale of 0 to 4: 0=normal food intake, l=difficulty with
swallowing some solids, 2=able to swallow only soft food, 3= able to swallow
liquids only, 4=complete dysphagia.
4.2.4 Quality of Life
Quality of life prior to intervention was assessed with three questionnaires. Patients
were asked to complete The Hospital Anxiety and Depression Scale (HAD)
(Appendix 1), the Short Form 36(SF36)(Appendix 2) and the EORTC QLQ -C30-
OES 24 (Appendix 3).
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HAD
The HAD questionnaire consists of questions each with a choice of graded
responses. It has been found to be a reliable instrument for detecting states of
depression or anxiety in a hospital population 317. The subscales provide a valid
measure of the severity of the emotional disorder.
SF 36
The SF36 is a general outcome measure. It uses eight health scales to measure three
aspects of health - functional status, well being, and "overall evaluation of health".
The responses to the questions on each scale are summed to provide eight scores
between 0 and 100. It has been shown to be a valid measure of the health status of a
wide range of patients 290.
EORTC QLQ -C30-OES 24
The EORTC QLQ -C30 core questionnaire consists of five functional scales, a
global health scale and three symptom scales. In addition there are six single items
assessing symptoms commonly found in cancer patients as well as a question about
the financial impact of the disease. All scores are linearly transformed such that
scales range from 0-100. A high score in the functional scales implies better
function, whereas a high score in the symptom scale and single items means more
symptoms. This basic questionnaire has previously been shown to have the
sensitivity to distinguish between two clinically different groups of patients with
oesophageal cancer 278.
The additional OES-24 consists of a further 24 questions specifically developed for
patients with oesophageal cancer 320 It aims to improve the sensitivity and specificity
of the core questionnaire to very small changes as a result of therapeutic
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intervention. As it was developed recently it was introduced midway through this
study.
4.2.5 Intervention
4.2.5.1 Endoscopic Laser therapy
Laser palliation was undertaken using either the ND: YAG fibrelase set at 90-100W
for 1 second bursts (Fibrelase, Living technology, Glasgow, Scotland); the Argon
Diode Laser set at 50W for 1 second bursts (Diomed 60W Surgical Diode Laser,
Diomed Ltd, Cambridge); or Argon Plasma Coagulation set at 50W (APC 300
ERBE, Eleckromedizin GmbH, Tubingen) by one of two experienced endoscopists
(Dr KR Palmer or Dr S Ghosh). Patients were sedated with a combination of
intravenous pethidine (25-75mg) and midazolam (2-7.5mg, Roche Ltd). An
Olympus GIFK endoscope (Keymed Ltd, Southend on Sea, UK) was used since this
facilitates optimum directed therapy. Whenever possible oesophageal dilatation was
avoided; when necessary the Olympus advanced dilators (Keymed Ltd) were used to
dilate strictures.
Laser therapy was repeated at four to six week intervals, according to the degree of
dysphagia.
4.2.5.2 Expandable metallic stent insertion
Expandable stents were inserted by an experienced consultant radiologist (Dr DC
Grieve) under radiological screening following intravenous sedation using titrated
doses of midazolam (2-10mg) One of three different types of stent was inserted.
Streker or the more modern Ultraflex (Medi-Tech/Boston Scientific, Watertown,
MA, USA) stents were deployed for proximal oesophageal strictures and tumours
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requiring stenting across the G-0 junction. If a fistula or perforation was suspected,
a covered Wallstent (Schneider, Bulach, Switzerland) was used.
All insertions of Ultraflex/Streker stents were preceded by balloon dilation of the
oesophagus using a 12mm Bluemax balloon (Medi-Tech) as recommended by the
stent manufacturers. Dilatation was not considered necessary when deploying the
Wallstents.
All patients undergoing a stent insertion received advice from a dietician concerning
the most appropriate types of food to eat to avoid a food bolus obstruction.
Any patients with dysphagia the day following stent insertion had a contrast swallow
to show an adequately stented lumen.
4.2.6 Follow-up
Following laser or intubation all patients received 40mg of omeprazole daily.
Dysphagia scores and quality of life questionnaires were serially assessed at monthly
intervals until death.
4.2.7 Costs
The cost of in-patient stay and treatment was based on that charged by the Western
General Hospitals Trust to Fund Holding GP's. Where specific charges did not exist,
the cost of the additional raw materials was added to a more basic cost code to give
an overall charge. For the laser therapy, the cost of the laser fibres was added to the
basic cost of an Upper GI Endoscopy. Similarly, for stenting the cost of the stent
was added to the basic cost of an x-ray Session.
4.3 Ethics
Ethical approval for the study was obtained from the Lothian Research Ethics
Committee. All patients gave written consent before being randomised into the trial.
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4.4 Statistical analysis
It was estimated that at least thirty-six patients should be studied to define a mean
difference of one point dysphagia score between the two groups at p<0.05 with 80%
power. Analysis was undertaken on the basis of intention to treat.
MannWhitney tests were used as appropriate.
4.5 Results
4.5.1 Patient details
The median age of the two groups, the median dysphagia score and tumour
characteristics of the two groups were similar at the time of initial therapy (Table
4.1).
Table 4.1 Characteristics of patients undergoing stent or laser therapy
Characteristics Laser(n=25) Stent(n=27)
Male 13 13
Median age,(range)years 77 (49-90) 77 (54-90)







Squamous cell carcinoma 9 7
Adenocarcinoma 15 10
Anaplastic 1 0
Small cell carcinoma 0 1
As six patients are still alive at the time of analysis they have been excluded from




All stent insertions were successful. A further 4 Ultraflex stents and 4 Wallstents
were placed in the laser treated patients (Table 4.2).
Table 4.2 Type of stent inserted








Streker/Ultraflex 4/7+4 10-15 18
Wallstent 16+4 10.5-11 20-22 6+4
LASER TREATMENT (n=23)
For those patients now deceased, a total of 95 laser sessions were undertaken (Nd:
YAG 66 sessions, Argon Diode Laser 26 sessions, Argon Plasma Coagulation three
sessions). At each session the median number of Joules applied was 3221(801-8881)
Joules. A total of 38 dilatations were carried out on these 23 patients giving a
median of one (0-14) dilatation per patient.
4.5.3 Survival
At the time of analysis two patients in the laser treated group were still alive at 70
and 244 days and four of the stented patients at 70,86,125, and 160 days. For the
remainder of patients median survival of laser patients was 125(17-546) days. This
was significantly longer than that of the stented patients, 56(8-315) days,
% =6.8,p=0.023. (Figure 4.1). The survival advantage of the laser patients over the
stented patients appears to be real and is not negated by the four stented patients
who were alive at the time of analysis.
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4.5.4 Additional therapy (Laser=23, Stent=23)
Six patients in the laser group and eight in the stented group also received additional
therapy. Four stented patients received radiotherapy, one for a metastatic spinal cord
compression and two for stridor. Two patients from each group had chemotherapy
with FAM. One patient in the stented group had previously had an oesophago-
gastrectomy and one had previously had an Atkinson tube, which was removed due
to migration. One of the laser patients had a gastrostomy tube inserted to improve
nutrition.
4.5.5 Complications and recurrent dysphagia (Laser=23,Stent=23)
Five laser treated patients developed significant complications. Oesophageal
perforation occurred during dilatation in one; three others developed tracheo-
123
oesophageal fistulae. All four patients were successfully palliated by use of covered
metallic stents. One patient receiving additional chemotherapy developed
neutropenia and died from pneumonia.
Four further patients randomised to laser therapy required stent insertion for
recurrent dysphagia.
One patient randomised to intubation suffered a fatal stroke 24 hours after stent
insertion. A further patient required injection with 1:100,000 Adrenaline into the
tumour following haemorrhage. Three patients presented with a food bolus
obstruction requiring disimpaction, two of whom developed aspiration pneumonia
from which they did not recover. Two further patients presented with late dysphagia
requiring dilatation alone (one), and laser therapy for tumour overgrowth (one).
4.5.6 Follow-up
All patients were followed up until death. This involved completion of dysphagia
scores at monthly intervals. Two patients in the laser treated group and two in the
stented group who were still alive at two months failed to complete the quality of
life questionnaires or dysphagia scores because they were too frail or declined to. In
all other patients quality of life questionnaires and dysphagia scores were
assiduously completed until death.
4.5.7 Dysphagia scores
All but one laser session and all stent placements were successful. However,
functional palliation of dysphagia was disappointing (Table 4.3 & 4.4). The median
change in dysphagia score at one month post treatment in both groups was nought.
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The figures remained similar at two and three months post-treatment, but small
numbers precludes further analysis. Three patients in the laser group and one in the
stented group reported an initial deterioration of swallowing at one month, which
subsequently improved, and this improvement was sustained.
Table 4.3 Actual dysphagia scores at baseline and one month
Dysphagia Laser at Stent at Baseline Laser at 1/12 Stent at
score Baseline 1/12
0 0 0 5 0
1 5 2 4 2
2 15 18 6 10
3 5 6 4 2
4 0 1 0 0
Table 4.4 Change in dysphagia scores at one month compared to baseline






4.5.8 Hospital stay and cost
The total median number of admissions and hospital stay for the laser group were
significantly longer than in the stented group (Table 4.5). This was due to the need
for repeated overnight inpatient stay for those patients undergoing laser therapy.
The total mean cost of therapy in the laser group was almost double that of the
stented group, again because of longer total hospital admission in the laser group.
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Table 4.5 Hospital Stay and Cost Per Patient
Laser Stent
Median Hospital Stay(range) days 24 (5-117) 10 (2-36)
Median No. of Admissions(range) 4(1-15) 1 (1-4)
Mean Cost ofHospital Stay(£) 4204 2278
Mean Cost of Therapy(£) 2031 1100
Total Mean Cost(£) 6235 3378
4.5.9 Quality of life
HAD
In the laser treated group 24% of patients were anxious at baseline which did not
change on follow-up. Twenty-four % of lasered patients were depressed at baseline
rising to 42% at one month. For the stented group, 22% of patients were anxious at
baseline, which rose to 38% at one month. Forty-one % of stented patients were
depressed at baseline rising to 61% at one month. (Table 4.6).
Table 4.6 Hospital Anxiety and Depression Index. Number of patients in each
category according to subscale scores
Scale scores Baseline Baseline One month One month
Laser n=25 Stent n=27 Laser n=19 Stent n=13
Anxiety
0-7 19 21 14 8
8-10 5 2 4 2
11-21 1 4 1 3
Depression
0-7 19 16 11 5
8-10 5 3 5 4
11-21 1 8 3 4
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SF36
At baseline, quality of life was globally impaired in both groups as compared to the
standard general population in all domains except emotional role Sanction and pain
(Table 4.7). There was no difference between the two groups in any domain at
baseline. At one month follow- up, the stented patients experienced significantly
more pain and had a significantly poorer emotional role function than the laser group
(p<0.05)
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Table4.7(1)Mean(SDscores,dian(range)danWh t yT stsfoSF36question aire BaselineMean (SD) n=25Laser, n=27StentBaseline Median(Range)
P
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There was no significant difference between the two groups in any category at the
baseline assessment (Table 4.8 & 4.9). At one month the stented group experienced
significantly more loss of appetite than the laser group.
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At baseline there were no significant differences between the two groups in any of
the domains (Table 4.10). At one month follow-up, there were significant
differences between the stented and laser groups in four categories. Stented patients
experienced significantly more pain, indigestion and a bad taste in the mouth than
the laser treated patients. Laser treated patients again reported a significantly better
emotional function.
There was no significant change in the dysphagia, deglutination or eating scores for
each group from baseline.
131

















































































































The aim of palliation in advanced oesophageal cancer is to overcome dysphagia and
optimise quality of life using interventions that have minimal complications. Our
series, like all others, has demonstrated how difficult this is to achieve.
The relief of dysphagia was disappointing and similar in patients treated by laser
therapy or intubation. Most patients reported no change in their overall quality of
swallowing one month after intervention and those who survived for several months
also stated that dysphagia persisted. This contrasts to the study reported by Adam et
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al 269 who reported a median of two-point improvement in dysphagia score in
patients intubated with expandable stents, compared to a median improvement of
one point in laser patients.
The disappointing results may be due to inclusion of an older, frailer group of
patients with more advanced disease and this is supported by the very poor survival
of both patient groups. It may also be due to the method of assessment which was by
independent patient completed questionnaire, as compared to physician assessment.
Blazeby et al have shown that there is poor correlation between doctors and patients
assessment of dysphagia 28\ Unlike other series, the "best dysphagia score" was not
recorded. This can be extremely short-lived and in our view is probably not a good
measure of significant benefit. Nevertheless, dysphagia did not generally progress in
either group and no patient died with absolute dysphagia.
Significant complications occurred after laser and intubation. It is likely that prior
radiotherapy contributed to the single oesophageal perforation that occurred in this
trial; endoscopists should be wary of dilatation following radiotherapy. It is possible
that oesophago-bronchial fistulae, observed in three patients, were a consequence of
repeated laser therapy. All of these occurred after multiple treatment sessions. Stent
migration, which has been a relatively commonly reported event following insertion
of stents across the gastro-oesophageal junction 253;3215 did not occur in this series,
possibly because Wallstents were not deployed at this site.
Late complications included recurrent dysphagia and some patients were crossed-
over to the alternative treatment option resulting in alleviation of dysphagia. It is
important that both stenting and ablative therapy are available when dealing with
advanced oesophageal cancer. Tumour in- or over-growth following stenting is
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probably best treated by laser, whilst fistulating and extensive circatrising tumours
are best managed by intubation.
In the trial the median survival of laser treated patients was significantly longer than
that of intubated patients. This has also been reported in another small study 271. This
observation may be an anomaly related to small sample size. It could alternatively
be due to tumour debulking or to a biological response following laser induced
tissue damage. A larger study is needed to confirm or refute the survival benefit of
laser palliation.
The major purpose of the interventions examined in this trial was to improve quality
of life rather than to prolong survival. Quality of life in advanced oesophageal
cancer is the product of several inter-relating factors including the degree of
dysphagia, pain and other physical symptoms and the psychological response to the
disease. Other studies have demonstrated that relief of dysphagia and improved well
OO/I *)QZ
being are poorly correlated ; ; and this was confirmed in our trial.
Collecting complete and accurate QOL data is not easy and several practical
difficulties arise particularly in an elderly and frail population. Other studies
measuring QOL in patients with oesophageal cancer have reported compliance rates
of 30-92%270;294;295;322. In this study, the combination of all of the questionnaires
was relatively long (106 questions). The compliance rate was 92%, two patients
from each group failing to complete the questionnaires at one month; all other
patients completed the questionnaires assiduously until just before death. This
compliance rate may have introduced biases into the quality of life data.
The generic questionnaires used in this study did, as expected, reveal significant
abnormalities in most patients. The findings of the SF36 and the EORTC-QLQC30
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were very similar, with global reductions in most aspects with particularly severe
reduction in mental health, lethargy and physical role function. Because survival was
so poor, the follow-up data were only meaningful for the first month after
intervention and it is noteworthy that at this time pain was more prominent in the
stented patients compared to the laser treated group. This may be related to pressure
effects exerted by the expanding stent upon mediastinal structures and was a
surprising but consistent finding. Pain following stent insertion tended to ease in the
few long term survivors after the first month.
The EORTC oesophageal module (OES24) revealed stented patients had more pain,
indigestion and troublesome taste at one month than the laser patients. The OES24
has been designed to increase the sensitivity and specificity of the EORTC QLQ C-
30 for patients with oesophageal cancer. It was able to reveal changes in Quality of
Life that other more crude measures failed to detect. As it has been recently
developed there is no literature on its use in clinical trials. However, it may prove to
be a useful tool to measure of quality of life in patients with oesophageal cancer in
future trials.
The information that the QOL questionnaires provided was clearly limited by poor
survival in this study, but these tools are user-friendly and provide useful
information concerning over-all well being. The degree of anxiety, measured by the
HAD questionnaire, varied widely but about a quarter of patients in both groups had
case-level anxiety at the time of randomisation. This level had increased in the
stented group at one month. A proportion of patients in each group were also
depressed, and this had increased in both stented and laser treated patients at one
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month. It may in future be useful to identify those patients who score highly for
anxiety or depression and offer specific intervention at any early stage.
This study has emphasised the difficulties encountered in palliation of advanced
oesophageal cancer. Future studies should measure quality of life issues, in addition
to the assessment of dysphagia.
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CHAPTER 5- Radical radiotherapy for oesophageal cancer
5.1 Introduction
Radiotherapy has several potential roles in the treatment of oesophageal cancer.
These include high dose, radical radiotherapy which attempts cure, adjuvant peri¬
operative radiotherapy to 'down-stage' tumours and improve the chance of cure by
surgical resection, and lower dose palliative radiotherapy which may relieve
dysphagia with minimal side effects but little effect upon survival.
In this chapter the efficacy of radical radiotherapy is addressed. The trial reported by
Pearson et al from the Western General Hospital influenced clinical practice for two
decades 323. This large retrospective analysis reported a one year survival rate of
44% and a 5 year survival rate of 22% for patients treated by radical radiotherapy
alone for oesophageal cancer. Twenty-five years later it was felt appropriate to
review this approach using a subsequent cohort, treated in the same institute.
Unfortunately, the early encouraging results of radical radiotherapy for oesophageal
cancer have never been reproduced. Earlam and Cunha-Melo reviewed more than
8000 patients treated by radiotherapy alone (some palliative) reported in 49 articles
in the period between 1954 and 1979. This was not a meta-analysis and they
calculated the mean 5-year survival of all these studies as 6%324. Palliation of
dysphagia was achieved in the majority of patients, but may take several weeks, and
up to 40% of patients developed a recurrent malignant stricture. In general, patients
selected for radiotherapy have a poor prognosis, either due to co-morbid disease,
locally advanced or metastatic disease.
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Adenocarcinoma of the oesophagus has often been considered to be radioresistant,
but there are data showing little difference in survival rates between patients with
adenocarcinoma and those with squamous carcinoma affecting the cardia treated
with radiotherapy 204. This is particularly relevant because adenocarcinoma of the
oesophagus and cardia are increasing in incidence. The use of radiotherapy in the
potentially curative setting requires doses of at least 5000cGy at 180-
200cGy/fraction.
Many more recent series have reported results of external beam radiation therapy
alone for oesophageal carcinoma. The majority of these series include patients with
unfavourable features such as lymph node involvement or locally advanced disease.
For example, in the study by De-Ren 184 of the 678 patients had stage-IV disease
325. Overall, the 5 year survival for patients with carcinoma of the oesophagus
treated with radiation therapy alone was approximately 10% (Table 5.1).
Table 5.1 Comparison of studies of radiation therapy alone for oesophageal cancer
Reference Histology Stage No. of patients 5-year survival (%)
Newaishy 1982
326
Squamous Inoperable 444 9





De-Ren 1989 Various II 177 22
325
III 501 28
Okawa et al have suggested that therapeutic results with radiation alone may only
equal those of surgery for T1 tumours 328. They treated 21 patients with T1-NO-MO
squamous cell carcinoma who refused surgery, or had significant co-morbidity with
a median total dose of 70Gy (range 50-76Gy). The five-year cause specific survival
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was 61.7%. Five patients had in-field local lymph node recurrence and another three
had lymph node recurrence outside the treatment field. The treatment was well
tolerated. Fourteen patients developed mild and two moderate oesophagitis.
The morbidity of radiotherapy depends on the dose, the technique, and whether the
patient received chemotherapy or underwent surgery. There are very limited toxicity
data presented in most series. An exception is the control arm of the RTOG 85-01
206 329 i_ *
study in which acute-radiation-related morbidity is well documented ; . In this
study, 60 patients received radiation therapy alone to a dose of 6400cGy. Acute
grade-Ill toxicity was 25%, and grade-IV toxicity was 3%. There were no treatment-
related deaths. Similarly, there are few reports of long-term radiation morbidity. In
general patients who receive radiation therapy alone have a 30-60% incidence of
oesophageal stricture, and almost half of these are associated with local recurrence
330
Locoregional failure remains one of the major problems for patients with
oesophageal cancer even after curative radiotherapy. In an analysis of six studies,
persistent or recurrent tumours were found in 56-85% of cases 33'. Neck and
mediastinal relapses occurred in 10-43% of cases and distant metastasis was
documented in 36-50% of cases. It has been surmised that one of the reasons for this
high relapse rate is that oesophageal cancers have a short potential doubling time
allowing repopulation of tumour cells during fractionation. Nishimura et al have
demonstrated a benefit of decreasing the treatment period with respect to local
tumour control 332. In this twice- daily treatment regime, 64 to 68Gy was given in 4
weeks instead of the conventional 6 weeks, resulting in local control rates at 1 year
of 47% versus 22%. Ten out of the 36 patients in the accelerated group developed
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benign stenosis. The authors conclude that total treatment time might have a
significant impact on local cure.
In order to shorten overall treatment time without causing acute toxicity, accelerated
radiotherapy has been given using a concomitant boost technique. In one study, 88
patients with oesophageal cancer, ineligible for surgery were given accelerated
fraction radiotherapy 333. In addition 64% of patients had neoadjuvant
chemotherapy. Sixteen percent of patients experienced grade 3 oesophagitis, and
oesophageal stenosis occurred in 8% of patients. Multivariate analysis demonstrated
that T stage and overall treatment time were prognostic factors for cause-specific
survival. T stage and neoadjuvant chemotherapy were independent adverse
prognostic factors for locoregional control.
The combination of chemotherapy and radiotherapy is based on the ideas of
enhanced antitumour activity and independent toxicity.
There are a number of single-armed trials of combined modality therapy alone for
oesophageal cancer ; " . In the trial reported by Coia, patients with stage I and
II disease were treated and analysed separately. Patients received 5-FU and
mitomycin C concurrently with 6000cGy. Combining stages I and II, the local
failure rate was 25% and the 5-year survival rate was 30%.
Four randomised trials have compared radiation therapy alone with combined
modality therapy 206;338-340 Unfortunately in three of the four trials inadequate doses
of systemic chemotherapy were delivered. The trial of the Radiation Therapy
Oncology Group 206 was the only one designed to deliver adequate doses of systemic
chemotherapy with concurrent radiation therapy. Patients had squamous cell
carcinoma and received four cycles of 5-FU and cisplatin. Radiation therapy
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(5000cGy) was given concurrently with chemotherapy, beginning on day 1. Only
about half the patients completed the four cycles of chemotherapy. The control
group received 6400 cGy of radiation therapy alone. At two years, patients who
received combined-modality therapy showed a significant improvement in survival
(38% Vs 10%) as well as significant decreases in local failure (44% Vs 65%) and
distant failure (12% Vs 26%). With longer follow-up the 3-year survival in the
combined modality group was 31%. There were no three-year survivors in the
radiation therapy control arm 329. Following this Poplin et al have reported the
results of intensive treatment consisting of high-dose radiotherapy (40 to50Gy) and
four courses of concurrent continuous infusion of 5-FU and cisplatin in 26 patients
with oesophageal cancer 341. Survival at 1 and 2 years was 65% and 50%
respectively, and the median survival of the patients with a complete response was
over 37 months. Only 12 patients received the prescribed dose of chemotherapy
owing to treatment toxicity. The authors concluded that a high frequency of local
tumour resolution was achieved at the cost of significant toxicity.
The Eastern Co-operative Oncology Group performed a similar randomised trial of
radiation therapy alone versus combined modality therapy 342. Patients had the
option of surgery after receiving 4000cGy, making the results more difficult to
interpret. An interim analysis revealed a significant improvement in median survival




Patients given a complete course of curative external beam radiotherapy (EBRT) (20
fractions to a total minimum dose of 4500cGy) for oesophageal cancer between
1989 and 1996 were identified from the database in the department of oncology, and
their records were reviewed. Details available directly from the database were age,
histology, site, date of the start of treatment, dose and number of fractions ofEBRT
and the date of death. Examination of the notes enabled further information to be
obtained including complications of treatment, concomitant therapies and cause of
death. Descriptions of swallowing, as assessed by a physician, both before and after
treatment were taken from the notes. These were converted a four-point scale




A total of 60 patients having radiotherapy with curative intent were identified.
Seventeen failed to complete the complete course of 20 fractions. Of the remaining
43 patients treated within this period, it was possible to obtain the hospital records of
41. Twenty -two of the patients were male, with a median age of 71 (range 53-85)
years. Histology in the majority of patients showed squamous cell carcinoma and
the site of the tumour was most commonly proximal (Table 5.2). The median length
of the tumour recorded in 33 patients was 5 (range 1-10) cms. Pre-treatment
assessment with either ultrasound scan or CT scan revealed 4 patients with local
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tumour invasion, 6 with lymph node involvement and 1 with a metastasis. The
median dose of EBRT was 5200 (range 4500-5488) cGy given in 20 fractions over
30 days.
Table 5.2 Patient Details
Male 22
Median age,(range)years 71(53-85)







Squamous cell carcinoma 34
Adenocarcinoma 5
Small cell cancer 1
Undifferentiated cancer 2
Spindle cell cancer 1
5.3.2 Survival
At the time of analysis 4 patients are still alive at 1591,1270,1494 and 1107 days.
For the remaining patients median survival was 255(range 42-1722) days (Figure).
Thirty-two patients died from carcinomatosis, five from other causes and two from
unknown causes. This gives a one-year survival of 40%, a two-year survival of 21%
and a five-year survival of 0%.
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Figure 5.1 Kaplan-Meier survival curve of curative radiotherapy for
oesophageal cancer
Time between first treatment and Death
(Days)
5.3.3 Tumour Recurrence and Complications
Eighteen (44%) patients had either a local or metastatic recurrence of disease at a
median of 195.5 (range 63-1207) days. During therapy, 10 (24%) patients suffered
from either oesophagitis or retrosternal chest pain and a further 11(27%) patients
reported a marked deterioration in their swallowing. Other complications of therapy
included 6(15%) patients with post-radiation strictures and 4(10%) with either
tracheo-oesophageal fistula or oesophageal perforation.
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5.3.4 Additional Therapy
Two patients had concomitant chemotherapy one with 5FU and the other with
MCVP 16. A further eighteen patients received a total of 23 additional therapies
(Table 5.3)
Table 5.3 Additional therapies
Type ofTherapy No. ofPatients Comments
Oesophageal Dilatation 10






Radiotherapy 3 2 for lymph node involvement
1 for intratracheal tumour
5.3.5 Dysphagia
Assessment of dysphagia score was possible in 39 (91%) patients, prior to and one
month following treatment (Table 5.4). Twelve patients showed an improvement in
their dysphagia score by at least one point, 17 reported no change in swallowing and
10 patients reported deterioration in swallowing by at least one point.
Table 5.4 Dysphagia Scores









EBRT provides the possibility of cure for those patients presenting with oesophageal
cancer who are unsuitable for radical surgery either because of comorbidity or
locally advanced disease.
This study examining the use of curative EBRT alone in 43 patients with
oesophageal cancer is limited by its retrospective nature. It reveals a five-year
survival of 0%, which is much poorer than other studies that have been reported in
the literature. Based on staging by ultrasound or CT scan these patients appeared to
be in a good prognostic group. However, staging based purely on these modalities is
crude compared with more sensitive investigations such as endoscopic and
laparascopic ultrasound. It is likely that a number of patients in this study were
understaged at initial presentation contributing to the poor survival. In the future it
may be possible to use other techniques to identify patients with oesophageal cancer
who will do well after radiotherapy. For example, Pomp et al have measured p53
using immunohistochemistry in patients with oesophageal cancer treated with
radiotherapy alone and showed that p53 overexpression was an independent
prognostic factor 343.
The technique ofEBRT involving administration of 5000Gy over 30 days is a fairly
standard technique. Survival can be enhanced if adjuvant chemo- and brachy-
therapy are used. It may no longer be appropriate to give EBRT alone to patients
with potentially curable oesophageal cancer.
Survival has traditionally been the main outcome measure for the assessment of
potentially curative treatments. In the case of oesophageal cancer, where even
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curative modalities result in a poor 5-year survival, other measures such as quality of
life and dysphagia should be more rigorously assessed and considered.
The high rate of tumour recurrence, either local or metastatic, of 44% is similar to
that reported in the literature 331. It may reflect initial failure to select patients in
whom there was really a possibility of cure or alternatively it may indicate
limitations of the treatment. As discussed previously, the rapid tumour doubling
time may allow repopulation of cells between radiotherapy fractions.
A high dose of EBRT results in a high complication rate. Acute complications of
oesophagitis or worsening dysphagia occurred during treatment in half of the
patients. A further 25% required additional therapies to overcome the later
complications of post radiation stricture and tracheo-oesophageal fistula. Again,
these complication rates are similar to those reported elsewhere 330.
Assessment of dysphagia was made purely from comments in the medical records
and translated onto the four-point dysphagia scale. Obviously this is a crude analysis
and also reflects the bias of a physician based rather than patient based assessment.
It has previously been shown that there is very poor correlation between doctors and
patients ratings of dysphagia 281. Reported improvement in swallowing at one month
was disappointing and may reflect the high incidence of oesophagitis that was
reported. Longer term swallowing was more difficult to assess as it was recorded
erratically in the notes, but would have been affected by both the occurrences of post
radiation strictures and local recurrence.
As several studies have shown improved survival rates without greater toxicity using
combination EBRT with either chemotherapy or brachytherapy for patients with
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potentially curable oesophageal cancer unsuitable for surgery, future research should
be directed towards refining these techniques. Other aspects of the disease should
also be considered and care of patients should also involve dieticians and palliative
care specialists. In a disease where currently survival with any treatment is poor,
further studies need to include outcome measures such as quality of life and
dysphagia scores.
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CHAPTER SIX- Summary and Conclusions
This thesis examines aspects of the treatment and prevention of oesophageal cancer.
Currently oesophageal cancer is becoming an increasing clinical problem due to its
rapidly rising incidence. If current rates of increase continue, this disease will
require more and more resources and expertise.
Barrett's oesophagus provides a model of cancer progression in a site, which allows
comparatively easy access to tissue specimens. Research into Barrett's oesophagus
is therefore relevant to our broader understanding of carcinogenesis and is obviously
relevant to oesophageal cancer particularly in the face of its rapidly increasing
incidence. The idea of reducing the incidence of oesophageal adenocarcinoma by
eradication of Barrett's oesophagus is an attractive one. The ideal treatment is one,
which is easily administered, easily tolerated, with little morbidity, reliably ablates
all Barrett's mucosa and is shown to reduce the cancer risk. Currently endoscopic
therapies are a long way from this ideal, but in the face of a fatal disease, which has
a potentially curable precursor strenuous efforts need to be made to refine these
techniques. So far different techniques have either shown incomplete ablation of the
Barrett's mucosa, for example APC, 319 or been associated with a high oesophageal
• 1 SI
stricture rate due to underlying muscle damage, for example PDT . Bown suggests
in a recent editorial that further improvement in results with APC is unlikely due to
the difficulty of applying it consistently to the whole of the mucosa surface 344 He
suggests that PDT, although requiring more research to develop a photosensitising
agent causing the optimum depth of mucosa necrosis without causing muscle
damage, has the better potential for treating the mucosa uniformly.
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The effect on cancer risk for such endoscopically treated patients, even in the
presence of a few remaining glands is unknown. The answer to this question can
only be obtained through follow-up of a large number of treated patients over many
years. Meanwhile, we are left with the option of screening patients with Barrett's
oesophagus with the hope of picking up early tumours at a curable stage. As this
represents a considerable practical undertaking it would be sensible to limit
screening to patients with Barrett's oesophagus identified as being at particularly
high risk for the development of a carcinoma. p53 staining and flow cytometry can
give an indication towards increased cancer risk, but are unable to reliably predict
individuals with Barrett's oesophagus who will develop an oesophageal cancer.
Certainly this should be a continuing area for research. As more endoscopic
therapies are developed, p53 staining and flow cytometry may provide more
information on the efficacy of such treatments before reduction in cancer risk can be
assessed.
Despite several theories, the aetiology of the rise in incidence of oesophageal cancer
needs to be explored further. More research needs to be undertaken into the impact
of proton pump inhibitors and Helicobacter Pylori infection on the development of
Barrett's oesophagus and oesophageal adenocarcinoma.
Oesophageal cancer is a cause of considerable morbidity and mortality. Initial
assessment should involve new and rigorous methods of disease staging such as
endoscopic and laparoscopic ultrasound. These techniques enable accurate staging
of disease and permit tailoring of treatment, whether curative or palliative to the
individual patient. Unfortunately, patients tend to present with advanced disease and
only a third of patients are potentially curable at this time. Education of the general
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public, and general practitioners about the symptoms of oesophageal cancer has
been a neglected area. As it increases in incidence, such information may encourage
patients to present early with symptoms of dysphagia and enable more patients to
present with potentially curable disease.
Most treatment studies have focussed on curative treatments for oesophageal cancer,
but such studies are relevant to only one third of patients with this disease. More
emphasis and research needs to be placed on methods of palliation. Palliative
therapy involves a multi-disciplinary approach involving, physicians, surgeons,
radiologists, oncologists and nutritionists. Standard routes of referral and treatment
for such patients need to be more clearly established than at present. Further good
randomised studies comparing different forms of palliation need to be performed so
that the optimum treatment can be offered to all individuals. Collaboration between
different specialities will enable combination therapies, such as radiotherapy and
stenting to be assessed. Treatment should not purely focus on the relief of dysphagia
but should also aim to optimise other aspects of health related quality of life.
For a disease with poor survival it is not good enough to look only at survival as an
endpoint for studies examining different therapies. The quality of life achieved by
such treatments also needs to evaluated. Measuring quality of life has many inherent
problems. It is generally very time consuming and requires considerable patience on
the part of both the interviewer and patient. Many patients with oesophageal cancer
are very frail and elderly and can find such questionnaires difficult to complete.
Performed serially they can give useful information for the individual patient.
Performed in the context of treatment studies, they enable broader conclusions to be
reached.
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In order to enable comparison between studies, similar well validated questionnaires
need to be used. The development of the EORTC-OES24 questionnaire goes a long
way to making the measurement of quality of life relevant to the particular problems
and concerns ofpatients with oesophageal cancer.
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ASSESSMENT OF HOW YOU ARE FEELING
For each question please tick the
1) I feel tense or "wound up"
Most of the time
A lot of the time
Time to time, occasionally
Not at all
2) I still enjoy the things I
used to enjoy
Definitely as much
Not quite as much
Only a little
Hardly at all
3) I get a sort of frightened feeling as
if something awful is about to happen
Very definitely and quite badly
Yes, but not too badly
A little, but it doesn't worry me
Not at all
4) I can laugh and see the funny
side of things
As much as I always could
Not quite so much now
Definitely not so much now
Not at all
5) Worrying things go through
my mind
A great deal of the time
A lot of the time
From time to time but not
too often
Only occasionally




Most of the time






jr which matches best how you feel
8) I feel as if I am slowed down




9) I get a sort of frightened feeling





10) I have lost interest in
my appearance
Definitely
I dont take quite so much
care as I should
I may not take quite as much care
I take just as much care as ever






12) I look forward with enjoyment
to things
As much as ever I did
Rather less than I used to
Definitely less than I used to
Hardly at all





14) I can enjoy a good book or






ASSESSMENT OF OVERALL HEALTH STATE
(SF36)
1) In general would you say your health is: (Tick one box)
Excellent Very good Good Fair Poor
2) Compared to one year ago, how would you rate
your health in general now? (Tick one box)
Much better than 1 year ago
Somewhat better now than 1 year ago
About the same as 1 year ago
Somewhat worse than 1 year ago
Much worse than 1 year ago
3) The following items are about activities you, might do
during a typical day. Does your health limit you in these
activities? If so how much? (Tick one box on each line)
Yes, Yes, No, not
limited limited limited
* a lot a little at all
a) Vigorous activities, such as running,
lifting heavy objects, particpating in strenuous
sports
b) Moderate activities, such as moving a table,
pushing a vacuum cleaner, or playing golf
c) Lifting or carrying groceries
d) Climbing several flights of stairs
e) Climbing one flight of stairs
f) bending, kneeling or stooping
g) Walking more than a mile
h) Walking more than half a mile
i) Walking one hundred yards
j) Bathing'or dressing yourself
4) During the past 4 weeks, have you had any of the following problems
with your work or other regular activities as a result of your physical health?
yes no
a) Cut down the amount of time you spent on work or other activities
b) Accomplished less than you would like
c) Were limited in the kind of work or other activities
d) Had difficulty performing the work or other activities
(for example it took extra effort)
5) During the past 4 weeks, have you had any of the following problems
with your work or other regular activities as a result of any emotional problems
(such as feeling depressed or anxious)
a) Cut down the amount of time you spent on work or other activities
b) Accomplished less than you would like
c) Didnt do work or other activities as carefully as usual
6) During the past 4 weeks, to what extent have your physical health or
emotional problems interfered with your normal social activities with
family, friends, neighbours or grbups?
Not at all Slightly Moderately Quite a bit Extremely
7) How much bodily pain have you had during the past 4 weeks?
None Very mild Mild Moderate Severe Very severe
8) During the past 4 weeks, how much did pain interfere with your normal work
(including both work outside the home and housework)?
Not at all A little bit Moderately Quite a bit Extremely
9) How much time during the past 4 weeks
Some of A little None of
the of the the
time time time
a) Did you feel full of life? T
b) Have you been a very
nervous person?
c) Have you been so down in the dumps
that nothing could cheer you up?
d) Have you felt calm and peaceful?
e) Did you have a lot of energy?
f) Have you felt downhearted and blue?
g) Did you feel worn out?
h) Have you been a happy person?
i) Did you feel tired?
j) Has your health limited your social
activities (like visiting with firends or 1
close relatives)?
10) During the past 4 weeks, how much of the time has your physical health
or emotional problems interfered with your social activities (like visiting
friends, relatives etc)?
All of the Most of Some of A little of None of
time the time the time the time the time
11) Please choose the answer that best describes how TRUE or FALSE each of
of the statements is for you.
Definitely Mostly Not Mostly Definitely
true true sure false false
a) I seem to get sick a little easier than
other people
b) I am as healthy as anybody I know
c) I expect my health to get worse
d) My health is excellent
All Most ^ good




EORTC QLQ-C30 (version 2.0.)
We are interested in some things about you and your health. Please answer all of the questions
yourself by circling the number that best applies to you. There are no "right" or "wrong" answers.
The information that you provide will remain strictly confidential.
Please fill in your inititals: I I I I I
Your birthdate (Day, Month, Year): I i I I I I I
Today's date (Day, Month, Year): 31 I I I I I I I
No Yes
1. Do you have any trouble doing strenuous activities,
like carrying a heavy shopping bag or a suitcase? 1 2
2. Do you have any trouble taking a long walk? 1 2
3. Do you have any trouble taking a short walk outside of the house? 1 2
4. Do you have to stay in a bed or a chair for most of the day? 1 2
5. Do you need help with eating, dressing, washing yourself or
using the toilet? 1 2
During the past week: Not at A Quite Very
All Little a Bit Much
6. Were you limited in doing either your work or other
daily activities? 12 3 4
7. Were you limited in pursuing your hobbies or other
leisure time activities? 12 3 4
8. Were you short of breath? 12 3 4
9. Have you had pain? 12 3 4
10. Did you need to rest? 12 3 4
11. Have you had trouble sleeping? 12 3 4
12. Have you felt weak? 12 3 4
13. Have you lacked appetite? 12 3 4
14. Have you felt nauseated? 12 3 4
15. Have you vomited? 12 3 4
Please ao on to the next page






16. Have you been constipated? 1 2 3 4
17. Have you had diarrhea? 1 2 3 4
18. Were you tired? 1 2 3 4
19. Did pain interfere with your daily activities? 1 2 3 4
20. Have you had difficulty in concentrating on things,
like reading a newspaper or watching television? 1 2 3 4
21. Did you feel tense? 1 2 3 4
22. Did you worry? 1 2 3 4
23. Did you feel irritable? 1 2 3 4
24. Did you feel depressed? 1 2 3 4
25. Have you had difficulty remembering things? 1 2 3 4
26. Has your physical condition or medical treatment
interfered with your family life? 1 2 3 4
27. Has your physical condition or medical treatment
interfered with your social activities? 1 2 3 4
28. Has your physical condition or medical treatment
caused you financial difficulties? 1 2 3 4
For the following questions please circle the number between 1 and 7 that best
applies to you
29. How would you rate your overall health during the past week?
1 2 3 4 5 6 7
Very poor Excellent
30. How would you rate your overall quality of life during the past week?
1 2 3 4 5 6 7
Very poor Excellent
® Copyright 1995 EORTC Study Group on Quality of Life. All rights reserved.
Version 2.0
EORTC QLQ - OES 24
Patients sometimes report that they have the following symptoms or problems. Please indicate the
extent to which you have experienced these symptoms or problems during the past week.
Not at A Quite Very
During the past week: all little a bit much
31. Could you eat solid foods? 12 3 4
32. Could you eat liquidised or soft foods? 12 3 4
33. Could you drink liquids? 12 3 4
34. Have you had trouble swallowing your saliva? 12 3 4
35. Have you choked when swallowing? 12 3 4
36. Have you had trouble enjoying your meals? 12 3 4
37. Have you felt full up too quickly? 12 3 4
38. Have you had troublesome eating? 12 3 4
39. Have you had troublesome eating in front of other people? 12 3 4
40. Have you had a dry mouth? 12 3 4
41. Have you had problems with your sense of taste? 12 3 4
42 Have you had troublesome coughing? 12 3 4
43. Have you had troublesome talking? 12 3 4
44. Have you had troublesome belching? 12 3 4
45. Have you had acid indigestion or heartburn? 12 3 4
46. Have you had trouble with acid or bile coming into your mouth? 12 3 4
47. Have you had pain when you eat? 12 3 4
48. Have you had pain in your chest? 12 3 4
49. Have you had pain in your stomach? 12 3 4
50. Have you worried about your weight being too low? 12 3 4
51. How much has your treatment been a burden to you? 12 3 4
52. How much has your illness been a burden to you? 12 3 4
53. Were you worried about your health in the future? 12 3 4
Complete this question only if you had hair loss
54. Were you upset by the loss of your hair? 12 3 4
Please do not use or copy without permission
